[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 905
1. Tsai CC, Liu YS, Huang EY, Huang SC, Chang HW, Tseng CW, ChangChien CC: Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecol Oncol; 2006 Mar;100(3):591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis.
  • OBJECTIVE: This investigation attempted to clarify the value of preoperative serum CA125 in predicting histopathological prognostic factors for early-stage cervical adenocarcinoma without lymph node metastasis.
  • METHODS: This study initially surveyed 163 patients with clinical stage Ib or IIa cervical adenocarcinoma treated with radical hysterectomy and pelvic lymphadenectomy.
  • Multivariate analysis revealed that among the preoperative clinicopathological variables, including age, tumor size, parametrial invasion, and CA125 level, raised CA125 most significantly influenced the assessment of the LVSI (P = 0.040) and depth of cervical stromal invasion (P = 0.002).
  • CONCLUSIONS: In early-stage cervical adenocarcinoma with negative pelvic lymph node metastasis, preoperative serum CA125 levels at the cutoff value of 26 U/ml impacted the determination of the poor histopathological prognostic factors.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. CA-125 Antigen / blood. Uterine Cervical Neoplasms / blood. Uterine Cervical Neoplasms / pathology


2. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


3. Cambruzzi E, Zettler CG, Alexandre CO: Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol Oncol Res; 2005;11(2):114-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma.
  • To estimate the association between human papillomavirus (HPV) status and the expression of p53, Ki-67 and bcl-2 in cases of endocervical adenocarcinoma, and the relation with squamous intraepithelial lesions (SIL) and age, 229 cases were selected, treated between 1995 and 2003 in the Hospital Nossa Senhora da Conceiçao.
  • The joint occurrence of endocervical adenocarcinoma and SIL were estimated too.
  • The presence of HPV, especially type 18 in endocervical adenocarcinoma suggests that this agent can be an important cofactor in the development and progression of glandular neoplasms of the uterine cervix.
  • The joint occurrence of endocervical adenocarcinoma and SIL may support this hypothesis.
  • HPV may promote an increased proliferation index in endocervical adenocarcinoma, shown by the expression of Ki-67.
  • [MeSH-major] Adenocarcinoma / virology. Ki-67 Antigen / metabolism. Papillomaviridae / pathogenicity. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Proliferation. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Cervix Uteri / virology. DNA, Viral / analysis. Female. Humans. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2003 Oct;82(10):960-5 [12956848.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):246-9 [2298414.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):379-85 [8834311.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):577-82 [2554717.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):547-51 [13678722.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1079-85 [10613340.001]
  • [Cites] Int J Gynecol Pathol. 2002 Apr;21(2):125-33 [11917221.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):14-8 [12079293.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):209-16 [8600071.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1655-60 [12168850.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):129-36 [10739702.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):309-15 [9042795.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):1-6 [14668542.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):834-42 [15105176.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):5-13 [11836697.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):243-51 [10757335.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Histopathology. 2002 Oct;41(4):313-21 [12383213.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):420-2 [11874072.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):15-22 [12821336.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):176-80 [9071723.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):884-91 [11420459.001]
  • [Cites] Int J Gynaecol Obstet. 1998 Dec;63(3):265-70 [9989896.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):113-7 [9465813.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):68-72 [14693839.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):957 [9038727.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2297-303 [8635035.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7 [11303584.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1291-9 [11002225.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):160-6 [11319292.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):53-60 [10385551.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):238-46 [11531273.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Aug;82(8):762-6 [12848649.001]
  • [Cites] APMIS. 2000 Mar;108(3):209-15 [10752690.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):49-53 [2703167.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):215-9 [12090589.001]
  • [Cites] Hum Pathol. 2000 Nov;31(11):1339-40 [11112206.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):95-103 [10393359.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):64-9 [8380284.001]
  • [Cites] Ann Med. 2003;35(7):458-65 [14649328.001]
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):393-7 [9626509.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):22-7 [8986528.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):899-904 [12378514.001]
  • (PMID = 15999157.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


Advertisement
4. Turan T, Kalantari M, Calleja-Macias IE, Cubie HA, Cuschieri K, Villa LL, Skomedal H, Barrera-Saldaña HA, Bernard HU: Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression? Virology; 2006 May 25;349(1):175-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a study designed to assess the methylation status of the HPV-18 genome, specifically of the late L1 gene, the adjacent long control region (LCR), and part of the E6 oncogene in cervical specimens with a range of pathological diagnoses.
  • In contrast, L1 sequences were strongly methylated in all cervical carcinomas, while the LCR and E6 remained unmethylated.
  • HeLa cells, derived from a cervical adenocarcinoma, contain chromosomally integrated HPV-18 genomes.
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cervix Uteri / virology. DNA Modification Methylases / antagonists & inhibitors. DNA-Binding Proteins / genetics. Enzyme Inhibitors / pharmacology. Female. HeLa Cells / virology. Humans. Oncogene Proteins, Viral / genetics. Proviruses / chemistry. Regulatory Elements, Transcriptional. Uterine Cervical Neoplasms / virology. Viral Proteins

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472835.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-91964
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Capsid Proteins; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / E6 protein, Human papillomavirus type 18; 0 / Enzyme Inhibitors; 0 / L1 protein, Human papillomavirus type 18; 0 / Oncogene Proteins, Viral; 0 / Viral Proteins; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


5. Datta NR, Rajkumar A, Basu R: Variations in clinical estimates of tumor volume regression parameters and time factor during external radiotherapy in cancer cervix: does it mimic the linear-quadratic model of cell survival? Indian J Cancer; 2005 Apr-Jun;42(2):70-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in clinical estimates of tumor volume regression parameters and time factor during external radiotherapy in cancer cervix: does it mimic the linear-quadratic model of cell survival?
  • AIMS: To quantify the parameters of tumor regression and time factor during EXTRT in cancer cervix.
  • [MeSH-major] Brachytherapy / methods. Neoplasm, Residual / pathology. Radiotherapy, Conformal / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cell Proliferation / radiation effects. Female. Humans. India / epidemiology. Linear Models. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Radiation Dosage. Reproducibility of Results. Retrospective Studies. Time Factors


6. Zhao Y, Lin H, Shen D, Xuan Y, Lin Z: Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. Pathol Int; 2008 Oct;58(10):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China.
  • The aim of the present study was to investigate the distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China.
  • HPV-DNA chip (oligonucleotide microarray) and cervical biopsy were used for 322 women in 1998-2005.
  • All the normal cervical epithelia were negative for HPV.
  • The positive rate of high-risk HPV was 33.9% in cervical intra-epithelial neoplasia (CIN)-1, 51.6% in CIN-2, 57.7% in CIN-3, 66.7% in cervical glandular intra-epithelial neoplasia (CGIN), 91.7% in squamous cell carcinoma (SCC), and 78.6% in adenocarcinoma.
  • HPV-16 was the major type in all CIN and SCC cervical lesions, but in cervical adenocarcinoma HPV-18 was the most common type, and HPV-16 was the second most common type.
  • Several cases of CIN-3, SCC and adenocarcinoma had multiple types of HPV, but there was none in CIN-1/2.
  • In summary, HPV-16 is the type most frequently involved in the development of SCC of the cervix, and this may be helpful for the prediction of the development and progress of CIN-2/3, whereas both HPV-18 and -16 play a prominent role in the development of adenocarcinoma and CGIN of the cervix in Yanbian, northern China.
  • [MeSH-major] Adenocarcinoma / virology. Alphapapillomavirus / genetics. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology


7. Hanley KZ, Tadros TS, Briones AJ, Birdsong GG, Mosunjac MB: Hematologic malignancies of the female genital tract diagnosed on liquid-based Pap test: Cytomorphologic features and review of differential diagnoses. Diagn Cytopathol; 2009 Jan;37(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical symptoms are often nonspecific and mimic other more common gynecologic malignancies such as squamous cell carcinoma of the cervix or endometrial adenocarcinoma.
  • Although cervico-vaginal (Pap) smear is the primary screening method for cervical squamous cell carcinoma and its precursors, it is far less sensitive for detection of other primary or metastatic malignancies.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Papanicolaou Test. Vaginal Smears


8. Kümmel S, Thomas A, Jeschke S, Hauschild M, Sehouli J, Lichtenegger W, Blohmer JU: Postoperative therapy modalities for cervical carcinoma. Anticancer Res; 2006 Mar-Apr;26(2C):1707-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative therapy modalities for cervical carcinoma.
  • Currently, the standard therapy for cervical carcinoma of FIGO stage IIB following adequate radical surgery is simultaneous radiochemotherapy with a platinous chemotherapeutic agent.
  • According to the current state of scientific knowledge, all patients of FIGO stages IIA-IB with at least one additional risk factor (adenocarcinoma, pN1, L1, V1, pT1b2) also benefit from adjuvant radiochemotherapy.
  • The data regarding a possible survival advantage following an increase in the hemoglobin content in the blood of cancer patients by erythropoietin administration is still contradictory.
  • Several studies are currently being conducted into the effectiveness of such new therapies on both life expectancy and quality of life (e.g., Cervix-NOGGO-AGO-Uterus 7-study).
  • [MeSH-major] Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617565.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Number-of-references] 63
  •  go-up   go-down


9. Tawfik El-Mansi M, Cuschieri KS, Morris RG, Williams AR: Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer; 2006 May-Jun;16(3):1025-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients.
  • Our aim was to determine the prevalence of human papillomavirus (HPV) types 16 and 18 in cervical adenocarcinoma (and its precursors) in Scottish patients.
  • We examined 119 cases of invasive adenocarcinoma, 20 cases of adenocarcinoma in situ, and 16 cases of normal glandular epithelium.
  • Our findings support that HPV-16, along with HPV-18, are likely to play a significant role in the pathogenesis of cervical adenocarcinomas and that cervical cancer screening strategies that incorporate oncogenic HPV testing, and prophylactic vaccines that target these types, will be beneficial for the reduction of adenocarcinoma and associated glandular precursors.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / etiology. Cervical Intraepithelial Neoplasia / virology. DNA Probes, HPV. Female. Genotype. Humans. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / etiology. Neoplasms, Glandular and Epithelial / virology. Polymerase Chain Reaction / methods. Polymorphism, Restriction Fragment Length. Prevalence. Scotland / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803480.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


10. Hatami M, Del Priore G, Chudnoff SG, Goldberg GL: Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy. Arch Iran Med; 2006 Oct;9(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy.
  • A 32-year-old female was diagnosed by loop electrosurgical excision procedure with adenocarcinoma in situ and a focus suspicious for positive lympho-vascular invasion.
  • We concluded that abdominal radical trachelectomy may be a surgical option for early stage cervical cancer treatment in young women who wish to preserve fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Electrosurgery. Female. Fertility. Humans. Intraoperative Complications. Postoperative Complications. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061618.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


11. Brys M, Semczuk A, Rechberger T, Krajewska WM: Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncol Rep; 2007 Jul;18(1):261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of the erbB-1/erbB-2 genes was measured applying the quantitative RT-PCR technique in 25 uterine carcinomas, 12 normal endometria, a carcinosarcoma and a case of botryoid sarcoma of the uterine cervix.
  • Concomitant erbB-1 and erbB-2 overexpression was detected only in 1 out of 25 (4%) uterine neoplasms. erbB-1 was overexpressed in a sarcoma botryoides of the uterine cervix.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Adenosquamous / genetics. Endometrial Neoplasms / genetics. Endometrium / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549377.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


12. Jain VS, Singh KK, Shrivastava R, Saumsundaram KV, Sarje MB, Jain SM: Radical radiotherapy treatment (EBRT + HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at a rural center in India. J Cancer Res Ther; 2007 Oct-Dec;3(4):211-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical radiotherapy treatment (EBRT + HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at a rural center in India.
  • AIM: To report the outcome of carcinoma of the uterine cervix patients treated radically by external beam radiotherapy (EBRT) and high-dose-rate (HDR) intracavitary radiotherapy (ICRT).
  • MATERIALS AND METHODS: Between January 1997 to December 2001, a total of 550 newly diagnosed cases of carcinoma of the uterine cervix were reported in the department.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy


13. Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM: Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol Oncol; 2007 Jun;105(3):662-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.
  • OBJECTIVE: Although the incidence of cervical adenocarcinoma is increasing, few genetic and epigenetic changes in its progression have been described.
  • We hypothesized that RASSF1A methylation and KRAS and BRAF mutations may play an important role in cervical adenocarcinoma.
  • METHODS: Archival primary carcinoma tissues (n=258) in uterine cervix consisting cervical adenocarcinomas (n=115) and squamous cell carcinomas (n=143) were evaluated for activating mutations of BRAF and KRAS and promoter hypermethylation of RASSF1A using methylation specific PCR and specific sequence analysis.
  • RESULTS: KRAS mutations were found in 16 adenocarcinomas (13.9%), while BRAF mutations were found in 5 (4.3%).
  • RASSF1A methylation was found in 27 adenocarcinomas (23.5%) and inversely correlated with KRAS and/or BRAF mutation (p=0.002) in cervical adenocarcinoma.
  • In cervical squamous cell carcinomas, KRAS mutations were detected only in 1 (0.7%) cases and RASSF1A hypermethylation was detected in 2 (1.4%).
  • The frequency of KRAS mutation and RASSF1A methylation were significantly different between adenocarcinomas (P<0.001) and squamous cell carcinomas (P<0.001).
  • RASSF1A hypermethylation and KRAS mutations and BRAF mutations are inversely correlated and play an important role in the development of adenocarcinomas.
  • CONCLUSIONS: These results are suggesting that these two histological types of cervical cancer arise through different molecular pathways in tumor development.
  • Different genetic/epigenetic alterations may explain the possible different therapeutic responsiveness between adenocarcinoma and squamous cell carcinoma of uterine cervix seen in clinic.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Genes, ras. Mutation. Proto-Oncogene Proteins B-raf / genetics. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17360030.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


14. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


15. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K: Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int; 2006 Jun;56(6):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
  • Many studies have suggested that human papillomavirus (HPV) infection plays an important role in the carcinogenesis of the cervical adenocarcinoma.
  • However, the prevalence of HPV infection in cervical adenocarcinoma and adenosquamous carcinoma varies among the studies.
  • Cervical adenocarcinoma (24 cases) and adenosquamous carcinoma (16 cases), including the underlying non-neoplastic epithelium were examined for HPV-DNA using in situ polymerase chain reaction (PCR), which enabled visualization of the localization on a glass slide.
  • In adenocarcinoma, HPV-DNA was found in 13 cases (54%) and in eight cases in underlying non-neoplastic epithelium, resulting in a total of 21 positive cases (88%).
  • In adenosquamous carcinoma, HPV-DNA was detected in 12 cases (75%) and and the HPV-DNA localization of each component was pure adenocarcinoma, 28.6%; mixed, 54.5%; and pure squamous cell carcinoma, 83.3%.
  • In the underlying non-neoplastic epithelium, HPV-DNA was found more frequently in the squamous epithelium (73.3%) than the cervical glands (6.3%).
  • In conclusion, HPV-DNA was detected in 54% of adenocarcinoma, and the rate was elevated by HPV localization in the underlying non-neoplastic epithelium.
  • HPV infection in the underlying squamous epithelium might be related to the carcinogenesis, even in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology


16. Schneider F, Mágori A, Orosz Z, Pulay T: [Atypical glandular cells (AGC) on Papanicolaou smears--the great challenge of cervix screening programs]. Orv Hetil; 2005 Oct 30;146(44):2239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Atypical glandular cells (AGC) on Papanicolaou smears--the great challenge of cervix screening programs].
  • PATIENTS: The aim of the study was to follow up patients with "atypical glandular cells of undetermined significance" (AGUS)/ "atypical glandular cells" (AGC), and adenocarcinoma cytological interpretation, based on a three-year material between 2000-2002 at the Department of Cytopathology of National Institute of Oncology, Hungary.
  • RESULTS: Out of 36193 conventional Papanicolaou smears, there were 276 AGC-NOS (AGUS, favour reactive in TBS1991) and 7 AGC-favour neoplastic (AGUS, favour neoplastic in TBS 1991) (altogether 0.78%) and 35 (0.1%) adenocarcinoma interpretations.
  • Histology was available in 136 (AGC-NOS: 106, AGC-favour neoplastic: 7 and adenocarcinoma: 23) cases.
  • [MeSH-major] Cervix Uteri / pathology. Mass Screening. Papanicolaou Test. Precancerous Conditions / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Hungary / epidemiology. Hyperplasia / diagnosis. Middle Aged. Pathology / standards


17. Jaidane M, Slama A, Bibi M: A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Nov;20(11):1393-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review.
  • We report the first case of an adenocarcinoma arising in an ectopic ureter in a woman and mimicking uterine cervical adenocarcinoma.
  • On gynecological exam, there were two cervixes with a small nodule on the left cervix.
  • After nodule biopsy, the initial diagnosis was adenocarcinoma of the uterine cervix.
  • Pelvic ultrasound and magnetic resonance imaging demonstrated an ectopic tumoral ureter draining a dysplastic pelvic kidney and inserted in the cervix of a bicornuate uterus.
  • Pathological exam demonstrated an adenocarcinoma arising in the ectopic ureter.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / diagnosis. Ureter. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy. Magnetic Resonance Imaging


18. Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M: Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol; 2006 Apr 28;12(16):2510-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.
  • AIM: Minimal deviation carcinoma of the uterine cervix, otherwise known as extremely well-differentiated adenocarcinoma (EWDA), is characterized by its benign microscopic appearance in contrast to its aggressive behavior.
  • METHODS: Clinicopathological features, including pre-operative biopsy diagnosis, were reviewed.
  • CONCLUSION: Unlike minimal deviation carcinoma of the cervix, these findings suggest that EWDA of the stomach is a lesion of low-grade malignancy.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Apr;91(4):839-48 [7513368.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):511-7 [8129036.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1161-6 [8813081.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):867-70 [9625834.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1719-29 [10223565.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):104-6 [10393360.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):279-87 [10746668.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):713-8 [10854531.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • [Cites] Histopathology. 2000 Dec;37(6):513-22 [11122433.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):869-73 [12064010.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Br J Cancer. 1980 Feb;41(2):209-21 [6989383.001]
  • [Cites] Biochem J. 1980 Nov 1;191(2):645-8 [7016112.001]
  • [Cites] J Exp Med. 1981 Oct 1;154(4):1249-54 [6945392.001]
  • [Cites] Acta Pathol Jpn. 1983 Mar;33(2):395-401 [6869006.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Int J Cancer. 1991 Jan 21;47(2):304-10 [1988372.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5879-85 [7680650.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):28-36 [8020672.001]
  • (PMID = 16688795.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MUC6 protein, human; 0 / Mucin-6; 0 / Mucins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4087982
  •  go-up   go-down


19. Mathew A, George PS: Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide. Asian Pac J Cancer Prev; 2009 Oct-Dec;10(4):645-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide.
  • The objective of the present paper is to summarize and quantify the trends in incidence and mortality rates of cervical squamous cell carcinoma (SCC) and adenocarcinoma (AC) worldwide.
  • All indexed publications, which provided information on time trends in incidence or mortality rates of cervix cancer, published during the past 12 years were included.
  • Cytology screening as well as changes in socio-economic profile have led to declines in cervical SCC incidence and mortality rates worldwide.
  • Increasing incidence and mortality rates of cervical AC has reported in many countries such as the US, Canada, UK, Iceland, Sweden, England, Spain, Finland, Slovakia, Slovenia, the Netherlands particularly among young women.
  • However the increase was mainly in earlier periods till 1995 and stable or declining trends in cervical AC have been observed in later periods in many of the above countries such as the US, UK, Canada, Sweden.
  • In conclusion, cytology screening in combination with HPV screening for high-risk HPV types may maximize the possibilities of having early cervical lesions detected and treated.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Squamous Cell / mortality. Papillomavirus Infections / mortality. Uterine Cervical Neoplasms / mortality


20. Zhang Y, Liang BL, Gao L, Ye RX, Shen J, Zhong JL: [Diffusion weighted imaging features of normal uterine cervix and cervical carcinoma]. Ai Zheng; 2007 May;26(5):508-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffusion weighted imaging features of normal uterine cervix and cervical carcinoma].
  • BACKGROUND & OBJECTIVE: Magnetic resonance imaging (MRI) is a feasible method to detect, diagnose and stage cervical cancer.
  • This study was to analyze the diffusion weighted imaging (DWI) features of normal uterine cervix and cervical carcinoma, and assess the values of DWI in diagnosis and monitor of cervical carcinoma after radiotherapy.
  • METHODS: Routine MRI sequence and axial diffusion weighted sequence (b=800 s/mm2) were performed in 20 patients with cervical carcinoma and in 16 healthy women as control.
  • The apparent diffusion coefficient (ADC) values of normal uterine cervix and cervical carcinoma were compared.
  • The ADC values of 7 cervical carcinoma patients before and after radiotherapy were compared.
  • RESULTS: Normal uterine cervix presented 3 layers in DWI.
  • The ADC value was significantly higher in normal uterine cervix than in cervical carcinoma [(1.71+/-0.14) x 10-3 mm2/s vs. (0.97+/-0.13) x 10(-3) mm2/s, P<0.01].
  • The ADC value of cervical carcinoma after radiotherapy was higher than that before radiotherapy [(1.49+/-1.40) x 10(-3) mm2/s vs. (1.02+/-0.06) x 10(-3) mm2/s], but was still lower than that of normal uterine cervix.
  • CONCLUSION: DWI could be used to distinguish cervical carcinoma from normal uterine cervix, evaluate the extension of cervical carcinoma before therapy, and monitor the treatment response of cervical carcinoma after radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Cervix Uteri / pathology. Female. Humans. Image Processing, Computer-Assisted / methods. Middle Aged. Neoplasm Invasiveness


21. Radić V, Kukura V, Ciglar S: Adenosquamous carcinoma of the uterine cervix--adjuvant chemotherapeutic treatment with paclitaxel and carboplatin; a case report. Eur J Gynaecol Oncol; 2005;26(4):449-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the uterine cervix--adjuvant chemotherapeutic treatment with paclitaxel and carboplatin; a case report.
  • Adenosquamous carcinoma of the uterine cervix is a rare mixture of malignant glandular and squamous epithelial elements.
  • We present a case of a 56-year-old woman with Stage IV cervical carcinoma treated with paclitaxel and carboplatin chemotherapy after cytoreductive surgery.
  • The patient died 20 months after establishing the diagnosis.
  • Paclitaxel in combination with carboplatin as adjuvant chemotherapeutic treatment could be another promising agent for patients with advanced metastatic cervical adenocarcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / therapy. Liver Neoplasms / therapy. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122201.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Sclerosing Solutions; 3K9958V90M / Ethanol; 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Ueda Y, Miyatake T, Okazawa M, Kimura T, Miyake T, Fujiwara K, Yoshino K, Nakashima R, Fujita M, Enomoto T: Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix. Am J Clin Pathol; 2008 Sep;130(3):389-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix.
  • We analyzed the clonality and human papillomavirus (HPV) infection status of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix to clarify their histogenesis.
  • HPV was in a mixed integrated-episomal form in a monoclonal GD, an adenocarcinoma in situ, and an adenocarcinoma.
  • These results imply that the concurrent glandular and squamous lesions are formed separately, whereas adenosquamous carcinoma is more likely to be a combination tumor of monoclonal origin, and that integration of HPV has an important role in the progression from polyclonal GD through monoclonal expansion to adenocarcinoma in situ and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Cervix Uteri / pathology. Cervix Uteri / virology. Endometrial Neoplasms / virology. Papillomavirus Infections / pathology
  • [MeSH-minor] Antibodies, Viral / analysis. Cervical Intraepithelial Neoplasia / immunology. Cervical Intraepithelial Neoplasia / pathology. Female. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Humans. Polymerase Chain Reaction

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701412.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


23. Urakami T, Sakai K, Asai T, Fukumoto D, Tsukada H, Oku N: Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography. Nucl Med Biol; 2009 Apr;36(3):295-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stereo-selective uptake and release of enantiomerically pure D- and L-[(18)F]FMT by rat C6 glioma cells and human cervix adenocarcinoma HeLa cells were examined.
  • Therefore, D-[(18)F]FMT would be a more powerful tool as a tumor-detecting agent for PET, especially for the imaging of a brain cancer and an abdominal cancer.

  • Hazardous Substances Data Bank. L-TYROSINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324275.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(18F)fluoromethyl-L-tyrosine; 0 / Radioactive Tracers; 42HK56048U / Tyrosine
  •  go-up   go-down


24. Torres MA, Jhingran A, Thames HD Jr, Levenback CF, Bodurka DC, Ramondetta LM, Eifel PJ: Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer; 2009 Aug;19(6):1107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter?
  • OBJECTIVE: The aim of this study was to investigate the relationship between marital status and outcome in women treated with concurrent chemoradiation (CT-RT) for locally advanced cervical cancer.
  • METHODS: We reviewed the records of all women who received CT-RT for squamous or adenocarcinomas of the cervix at the M. D.
  • Anderson Cancer Center between 1998 and 2005.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Marital Status. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Social Class. Treatment Outcome


25. Sosnovski V, Barenboim R, Cohen HI, Bornstein J: Complex Nabothian cysts: a diagnostic dilemma. Arch Gynecol Obstet; 2009 May;279(5):759-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Multiple and large cysts, located in the cervical stroma, can cause significant enlargement of the cervix.
  • CONCLUSION: In rare cases in which the intracervical cysts assume very large dimensions, ultrasound and MRI can aid diagnosis, but may not always prevent the need for excision or hysterectomy.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Cysts / diagnosis. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Colposcopy. Diagnosis, Differential. Female. Frozen Sections. Humans. Hysterectomy. Magnetic Resonance Imaging. Metaplasia


26. Shekari M, Sobti RC, Kordi Tamandani DM, Suri V: Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population. Arch Gynecol Obstet; 2008 Dec;278(6):517-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population.
  • Cervical cancer continues to be the most common cause of death among women in developing countries.
  • In this work, we have conducted a case-control study to assess the role of these two polymorphisms in cervical cancer development.
  • We obtained blood samples from 200 women with cervical cancer and from equal matched controls and analysed using PCR-RFLP method.
  • We found that the methylenetetrahydrofolate reductase variant CT and CT+TT genotypes decreased cervix cancer risk, statistically significant (OR:0.30, 95% CI: 0.18-0.51, P<0.001 for CT and OR:0.29, 95% CI: 0.18-0.49, P=0.0000006 for CT+TT).
  • Similarly in those patients who used oral contraceptive with variant CT genotype, there was statistically highly significant reduced risk of cervix cancer (OR:0.25, 95% CI: -0.12-0.49, P<0.001) of methylenetetrahydrofolate reductase gene.
  • For the methionine synthase, 2756 variant AG and AG+GG genotypes were similarly associated with highly significant reduced risk of cervix cancer (OR: 0.13, 95% CI: 0.07-0.26, P<0.001 for AG, and OR: 0.15, 95% CI: 0.08-0.27, P<0.001 for AG+GG) genotypes.
  • In conclusion, our study suggested that methylenetetrahydrofolate reductase and methionine synthase polymorphisms might have protective effect on the risk of cervical cancer in the North Indian women.
  • [MeSH-major] 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / genetics. Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351371.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.13 / 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
  •  go-up   go-down


27. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C: Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol; 2006 Aug;102(2):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience.
  • Eighteen patients had cervix cancer (5 stage IA2 and 13 stage IB1), and 2 had endometrial cancer (1 stage IB and 1 stage IIIA).
  • Among those with cervix cancer, 12 had adenocarcinoma, 4 squamous cell carcinoma, and 2 adenosquamous carcinoma.
  • [MeSH-major] Endometrial Neoplasms / surgery. Hysterectomy / methods. Laparoscopy / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Feb;104(2):501; author reply 501-3 [17157902.001]
  • (PMID = 16472844.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Macdonald RD, Kirwan J, Hayat K, Herrington CS, Shawki H: Villoglandular adenocarcinoma of the cervix: clarity is needed on the histological definition for this difficult diagnosis. Gynecol Oncol; 2006 Jan;100(1):192-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular adenocarcinoma of the cervix: clarity is needed on the histological definition for this difficult diagnosis.
  • BACKGROUND: Villoglandular adenocarcinoma (VGA) of the cervix is reported as a variant of a cervical adenocarcinoma with a good prognosis.
  • CASES: We present two cases histologically reported as a villoglandular adenocarcinoma of the cervix that have recurred and progressed rapidly since initial treatment.
  • External histopathological review suggested both had a prominent villoglandular pattern but with an associated underlying well-differentiated adenocarcinoma.
  • CONCLUSION: The diagnosis of VGA is difficult.
  • Because of the rarity of VGA and the difficulty but importance of the diagnosis, we would feel that a central review of all cases of VGA is warranted.
  • This would assist in diagnosis and also in obtaining accurate follow-up data.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology


29. Lucey BP, Nelson-Rees WA, Hutchins GM: Henrietta Lacks, HeLa cells, and cell culture contamination. Arch Pathol Lab Med; 2009 Sep;133(9):1463-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Henrietta Lacks died in 1951 of an aggressive adenocarcinoma of the cervix.
  • The cancer cells, now called HeLa cells, grew rapidly in cell culture and became the first human cell line.
  • Cultures, supposedly of tissues such as breast cancer or mouse, proved to be HeLa cells.
  • [MeSH-major] Adenocarcinoma / history. Cell Culture Techniques / history. Cervical Intraepithelial Neoplasia / history. HeLa Cells. Medical Oncology / history. Uterine Cervical Neoplasms / history


30. Takeuchi K, Tsujino T, Sugimoto M, Yoshida S, Kitazawa S: Endocervical adenocarcinoma associated with lobular endocervical glandular hyperplasia showing rapid reaccumulation of hydrometra. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1285-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinoma associated with lobular endocervical glandular hyperplasia showing rapid reaccumulation of hydrometra.
  • Mucinous endocervical adenocarcinoma is characterized by increased watery vaginal discharge, but the early diagnosis is sometimes difficult because biopsy specimen might only serve to sample a superficial part of the tumor.
  • Papanicolaou smear of endocervix and endometrium followed by fractional curettage was performed, but failed to confirm the diagnosis.
  • To investigate the unknown origin of hydrometra, an exploratory laparotomy with total hysterectomy and bilateral salpingo-oophorectomy was performed, followed by pelvic lymphadenectomy because biopsy specimens during operation suggested adenocarcinoma of the cervix.
  • The final pathologic study of surgical specimens revealed mucinous adenocarcinoma, which was located on the proximal area of cervix.
  • Pyloric gland mucin (HIK1083), MUC6, and MUC5AC were diffusely immunopositive in the cytoplasm of LEGH cells and the immunoreactivity became weaker in adenocarcinoma cells with tumor progression and loss of differentiation.
  • Based on histopathologic features of the present case, there seems to be a possible link between LEGH and conventional mucinous endocervical adenocarcinomas.
  • The physician should keep in mind the possible existence of endocervical adenocarcinoma in a patient showing rapid reaccumulation of hydrometra, when uterine malignancies are clinically suspected and biopsy finding fails to confirm the diagnosis.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217972.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Hao H, Tsujimoto M, Tsubamoto H, Komori S, Hirota S: Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix. Pathol Int; 2010 Jul;60(7):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix.
  • Immunohistochemical phenotype of these glands was compared with three normal uterine endocervices and two cases of well-differentiated mucinous adenocarcinoma of the uterine cervix.
  • On the other hand, only glands of well-differentiated mucinous adenocarcinoma expressed human gastric mucin and showed high proliferative index of Ki-67.
  • Furthermore, diffuse distribution of estrogen and progesterone receptors, lack of human gastric mucin and low proliferative activity were distinct features for endocervicosis compared to well-differentiated mucinous adenocarcinoma.
  • [MeSH-major] Cervix Uteri. Choristoma / pathology. Urinary Bladder Diseases / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Cesarean Section. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Phenotype. Pregnancy. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


32. Delotte J, Ferron G, Kuei TL, Mery E, Gladieff L, Querleu D: Laparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervix. J Minim Invasive Gynecol; 2009 Jan-Feb;16(1):106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervix.
  • Transposition of the ovaries is performed frequently in young women with early-stage cervical cancer.
  • However, this must be balanced with the risks of ovarian metastases especially in patients with adenocarcinomas.
  • We report the first case of laparoscopic management of an isolated metastasis to a transposed ovary that occurred 2 years after primary laparoscopic treatment of a stage IB1 adenocarcinoma of the cervix.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Lymph Node Excision. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Ovariectomy / methods. Uterine Cervical Neoplasms / pathology


33. Lin Z, Gao M, Zhang X, Kim YS, Lee ES, Kim HK, Kim I: The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions. J Cancer Res Clin Oncol; 2005 Jun;131(6):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions.
  • PURPOSE: This study is aimed at investigating the significance of gene promoter methylation status and protein expression of p16 INK4A and O6-methylguanine-DNA methyltransferase (MGMT) in the various uterine cervical lesions.
  • MATERIALS AND METHODS: Methylation status by using methylation-specific polymerase chain reaction (MS-PCR) and protein expression by using immunohistochemistry for p16 INK4A and MGMT genes were performed in cervical squamous intraepithelial neoplasms (CIN), invasive squamous cell carcinomas (SCC), adenocarcinomas and non-neoplastic cervices.
  • RESULTS: None of 20 non-neoplastic cervices showed p16 INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma. p16 INK4A protein was totally negative in non-neoplastic cervices, but positive with 90.0% of CIN I, 100% of CIN II-III and adenocarcinoma, and 78.7% of SCC.
  • MGMT protein was expressed in 10% of non-neoplastic cervices, but significantly increased in SCC (42.5%) and adenocarcinoma (70.0%).
  • CONCLUSIONS: The hypermethylation of p16 INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16 INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / metabolism. DNA / metabolism. DNA Repair. Female. Gene Silencing. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1517-23 [14562026.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):11-6 [11905599.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93 [7603984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 May;43(5):1344-9 [11980845.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):371-9 [11986189.001]
  • [Cites] Neurol Res. 2003 Apr;25(3):241-8 [12739231.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):319-24 [9159345.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]
  • [Cites] Diagn Mol Pathol. 1998 Dec;7(6):324-30 [10207671.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):435-40 [15099958.001]
  • [Cites] Mol Carcinog. 1999 Feb;24(2):90-8 [10078936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 [9751761.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4531-5 [7553622.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):433-9 [9521167.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5360-8 [9393761.001]
  • [Cites] J Biol Chem. 1983 Feb 25;258(4):2327-33 [6822564.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):826-32 [10814678.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):200-7 [15279712.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2981-4 [12912945.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14 [12237286.001]
  • [Cites] Am J Obstet Gynecol. 2004 Mar;190(3):674-9 [15041998.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Cell. 1981 Apr;24(1):33-40 [6263490.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1982-6 [11448914.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):584-9 [11297252.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(6):547-55 [8612308.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):26-34 [9887097.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):69-72 [9662253.001]
  • [Cites] Pathol Int. 2002 May-Jun;52(5-6):375-83 [12100520.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3416-20 [8324751.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):689-96 [15188135.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):337-40 [1738185.001]
  • [Cites] Oncology. 1999;56(1):83-7 [9885382.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Cell. 1988 Apr 8;53(1):3-4 [3280142.001]
  • [Cites] Trends Cell Biol. 1994 Jan;4(1):15-8 [14731824.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):299-304 [11531283.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):577-84 [9816206.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1004-14; discussion 1014 [14675710.001]
  • [Cites] Carcinogenesis. 1998 Jul;19(7):1247-50 [9683184.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):807-10 [10029067.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4131-4 [1868433.001]
  • (PMID = 15785933.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


34. Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ, Wurscher M, Johnson LG, Galloway DA, Daling JR: Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer; 2007 Feb 1;120(3):650-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.
  • Human papillomavirus (HPV) is the central etiologic factor for cervical cancer, and prior studies suggested C. trachomatis may act as an HPV cofactor.
  • We examined the C. trachomatis-cervical cancer association by serotype, histology, HPV type in the tumor, and other HPV cofactors.
  • We conducted a population-based study in the Seattle-Puget Sound area of 302 women with invasive squamous cell carcinomas (SCC), 185 women with adenocarcinomas of the cervix (AC), and 318 HPV seropositive control women.

  • Genetic Alliance. consumer health - Cervical cancer.
  • Genetic Alliance. consumer health - Chlamydia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Chlamydia Infections.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):35-9 [10585579.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):423-30 [10712889.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1911-9 [10837170.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):221-7 [10861478.001]
  • [Cites] JAMA. 2001 Jan 3;285(1):47-51 [11150108.001]
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):153-61 [11246844.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1934-40 [11280749.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1368-77 [11283058.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7 [11303584.001]
  • [Cites] J Infect Dis. 2002 Feb 1;185(3):324-31 [11807714.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):572 [12228133.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):681-2 [14520711.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):431-9 [15221973.001]
  • [Cites] Epidemiology. 2004 Jul;15(4):422-7 [15232402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1624-30 [15466979.001]
  • [Cites] JAMA. 1986 Apr 4;255(13):1730-4 [3081742.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1706-11 [3815368.001]
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1272-8 [1328880.001]
  • [Cites] J Clin Microbiol. 1992 Nov;30(11):2911-6 [1452662.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):955-7 [7909014.001]
  • [Cites] Curr Top Microbiol Immunol. 1994;186:101-19 [8205836.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8 [8827359.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):31-4 [9036866.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):233-7 [9107427.001]
  • [Cites] Clin Dermatol. 1997 Mar-Apr;15(2):249-59 [9167909.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):25-31 [9212727.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] J Infect Dis. 1998 Jun;177(6):1710-4 [9607854.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):20-5 [10406360.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):110-5 [15756673.001]
  • [Cites] Am J Epidemiol. 2005 Oct 1;162(7):668-75 [16120706.001]
  • [Cites] Med J Aust. 2005 Nov 21;183(10):548-9 [16296981.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1481-95 [16206285.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1995;64:1-378 [16755705.001]
  • (PMID = 17096345.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA094741-02; United States / NCI NIH HHS / CN / N01 CN067009; United States / NCI NIH HHS / CA / P01CA042792; United States / NCI NIH HHS / CA / CA094741-02; United States / NCI NIH HHS / CA / R03 CA094741; United States / NCI NIH HHS / CN / N01-CN-67009; United States / NCI NIH HHS / CA / P01 CA042792; United States / NCI NIH HHS / CA / R03CA94741
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antibodies, Viral; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS142339; NLM/ PMC4049152
  •  go-up   go-down


35. Martínez-Monge R, Gaztañaga M, Aramendía JM, Cambeiro M, Arbea L, Espinós J, Aristu JJ, Jurado M: A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer. Int J Gynecol Cancer; 2010 Jan;20(1):133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
  • OBJECTIVES: This study was undertaken to determine the tolerability of a 7-week schedule of external beam radiation therapy, high-dose-rate brachytherapy, and weekly cisplatin and paclitaxel in patients with locally advanced carcinoma of the cervix.
  • METHODS: Twenty-nine patients with International Federation of Gynecology and Obstetrics stages IB2 to IVa cervical cancer were treated with 40 mg/m per week of intravenous (i.v.) cisplatin and 50 mg/m per week of i.v. paclitaxel combined with 45 Gy of pelvic external beam radiation therapy and 30 Gy of high-dose-rate brachytherapy.
  • CONCLUSIONS: This study demonstrated unacceptable toxicity of combining the stated doses of concurrent cisplatin and paclitaxel chemotherapy with definitive radiotherapy for patients with advanced cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Paclitaxel / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Invasiveness. Patient Compliance. Time Factors. Treatment Outcome


36. Lavie O, Segev Y, Peer G, Gutterman E, Sagie S, Auslnader R: Conservative management for villoglandular papillary adenocarcinoma of the cervix diagnosed during pregnancy followed by a successful term delivery: a case report and a review of the literature. Eur J Surg Oncol; 2008 May;34(5):606-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management for villoglandular papillary adenocarcinoma of the cervix diagnosed during pregnancy followed by a successful term delivery: a case report and a review of the literature.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Conization. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


37. Silva-Filho AL, Reis FM, Traiman P, Pedrosa MS, Miranda D, Triginelli SA: Clinicopathological features influencing pelvic lymph node metastasis and vaginal and parametrial involvement in patients with carcinoma of the cervix. Gynecol Obstet Invest; 2005;59(2):92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features influencing pelvic lymph node metastasis and vaginal and parametrial involvement in patients with carcinoma of the cervix.
  • PURPOSE: This study was undertaken to evaluate clinical and pathologic findings that predicted pelvic lymph node metastasis and parametrial and vaginal involvement in patients with stage IB carcinoma of the cervix.
  • METHODS: 71 patients with diagnosis of stage IB (FIGO) cervical cancer were prospectively studied from December 1997 to August 2002.
  • The histological classification identified squamous cell carcinoma in 60 patients (84.5%) and adenocarcinoma in 11 patients (15.5%).
  • CONCLUSION: The presence of LVSI is significantly associated with pelvic lymph node metastasis and vaginal and parametrial involvement in patients with stage IB cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Pelvic Neoplasms / secondary. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / secondary


38. Klemm P, Tozzi R, Köhler C, Hertel H, Schneider A: Does radical trachelectomy influence uterine blood supply? Gynecol Oncol; 2005 Feb;96(2):283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does radical trachelectomy influence uterine blood supply?
  • OBJECTIVE: Radical trachelectomy in combination with pelvic and parametric lymphadenectomy is indicated in young patients with early cervical cancer and planned pregnancy.
  • We evaluated if uterine blood supply is decreased after radical trachelectomy as one of various possible causes of preterm birth.
  • METHODS: Between October 2003 and April 2004, 14 consecutive patients with early cervical cancer underwent radical trachelectomy with pelvic and parametric lymphadenectomy.
  • The uterine blood supply was measured as resistance index (RI) by Doppler sonography pre- and postoperatively.
  • Doppler sonography of the uterine artery was also performed in 14 healthy students as a control cohort.
  • RESULTS: Fourteen patients with histologically confirmed adenocarcinoma or squamous carcinoma of the cervix uteri stage Ia1 L1 to 1b1 underwent radical trachelectomy.
  • On average, 11.5 mm (5-23) of cervical length and 24.6 (14-35) tumor-free lymph nodes were removed.
  • Decrease of RI of the uterine artery was 0.06 on the right side (0.76-0.70) and 0.07 (0.75-0.68) on the left side.
  • CONCLUSION: Uterine perfusion after radical trachelectomy with pelvic and parametric lymphadenectomy remains unchanged.
  • [MeSH-major] Gynecologic Surgical Procedures / adverse effects. Uterine Cervical Neoplasms / surgery. Uterus / blood supply
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymph Node Excision / adverse effects


39. Takai N, Nasu K, Miyakawa I: Management of patients with carcinoma of the cervix with anuric renal failure. Int J Gynaecol Obstet; 2005 Feb;88(2):156-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with carcinoma of the cervix with anuric renal failure.
  • [MeSH-major] Anuria / epidemiology. Renal Insufficiency / epidemiology. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Comorbidity. Female. Humans. Middle Aged. Nephrostomy, Percutaneous

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694098.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol; 2005 Feb;22(1):3-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspects of immunohistochemistry (IHC), which are useful in the diagnosis of ovarian tumors (mostly neoplasms but also a few tumor-like lesions), are discussed.
  • IHC for neuroendocrine markers may assist in the diagnosis of primary and metastatic carcinoid tumor.
  • The broad differential diagnosis of glandular neoplasms with an endometrioid-pseudoendometrioid morphology, or mucinous cell type, has been the subject of much exploration in recent years, particularly the distinction between primary and metastatic neoplasms.
  • The well-known CK7 positive, CK20 negative phenotype of primary endometrioid carcinoma, and the converse profile in most metastatic large intestinal adenocarcinomas with a pseudoendometrioid morphology, has been much publicized but albeit an appropriate supportive adjunct in many cases, exceptions from the typical staining pattern may be encountered.
  • The rare differential of metastatic cervical adenocarcinoma versus primary ovarian mucinous or endometrioid carcinoma may be aided by strong p16 staining of the former.
  • Staining for alpha-fetoprotein may aid in confirming the diagnosis of endometrioid-like (and hepatoid) variants of yolk sac tumor.
  • As in tumor pathology in general, various markers may be crucial in the diagnosis of small round cell tumors of the ovary, and familiar markers of epithelial, lymphoid, leukemic, and melanocytic neoplasms may assist in the analysis of high grade tumors with a poorly differentiated carcinoma, lymphoma-granulocytic sarcoma, malignant melanoma differential.
  • [MeSH-major] Immunohistochemistry. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Ovarian Cysts / diagnosis. Ovarian Follicle / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512597.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 115
  •  go-up   go-down


41. Hebbar V, Damera G, Sachdev GP: Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer; 2005 Sep 27;5:124
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of MUC genes in endometrial and cervical tissues and tumors.
  • The objective of this study was to investigate the expression of human MUC genes (MUC1, MUC2, MUC5B, MUC5AC and MUC8) in human endometrium and cervix, and to compare and quantitate the expression of MUC genes in normal and cancerous tissues.
  • RESULTS: Of the five-mucin genes studied, MUC1, MUC5B and MUC8 showed high expression levels in the normal and cancerous endometrial and cervical tissues, MUC2 and MUC5AC showed considerably lower expression.
  • Statistically, higher levels of MUC1, MUC5B and MUC8 were observed in endometrial adenocarcinomas compared to normal tissues.
  • In contrast, only MUC1 levels increased with no significant changes in expression of MUC5B and MUC8 in cervical tumors over normal cervical tissues.
  • Only MUC1 appears to be increase, in cervical tumors.
  • Low to neglible levels of MUC2 and MUC5AC were observed in all studied endometrial and cervical tissues.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):118-26 [8604237.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):856-61 [11093805.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 28;1406(3):251-9 [9630659.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15386-96 [11278696.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] J Korean Med Sci. 2002 Feb;17(1):29-33 [11850585.001]
  • [Cites] J Pathol. 2002 Aug;197(5):632-7 [12210083.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Jpn J Clin Oncol. 2002 Dec;32(12):525-9 [12578901.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Mar;28(3):267-70 [12594051.001]
  • [Cites] Am J Reprod Immunol. 1996 Mar;35(3):261-6 [8962658.001]
  • [Cites] Fertil Steril. 1996 Aug;66(2):316-26 [8690123.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Mar;16(3):232-41 [9070607.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):999-1011 [9096884.001]
  • [Cites] J Surg Oncol. 2003 Aug;83(4):253-60 [12884239.001]
  • [Cites] Hum Reprod. 1988 Oct;3(7):826-34 [3182973.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Hum Reprod. 1989 Apr;4(3):236-42 [2469695.001]
  • [Cites] Biochem J. 1990 Mar 15;266(3):757-63 [1691631.001]
  • [Cites] Eur J Biochem. 1990 May 20;189(3):475-86 [2112460.001]
  • [Cites] Tumour Biol. 1990;11(5):274-86 [1697426.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] J Reprod Fertil. 1991 Jul;92(2):525-41 [1886107.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):57-92 [1727693.001]
  • [Cites] Am J Physiol. 1992 Oct;263(4 Pt 1):L413-29 [1415719.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):557-64 [1449803.001]
  • [Cites] Fertil Steril. 1993 Dec;60(6):1011-9 [7694876.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] Eur J Biochem. 1994 Sep 1;224(2):787-95 [7925397.001]
  • [Cites] Crit Rev Oncol Hematol. 1994 Dec;17(3):153-80 [7865137.001]
  • [Cites] Hum Reprod. 1995 Jan;10(1):98-102 [7745080.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Endocrinology. 1995 Aug;136(8):3639-47 [7628404.001]
  • [Cites] Biol Reprod. 1999 Jan;60(1):58-64 [9858486.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Ann Thorac Surg. 1999 Mar;67(3):810-4 [10215233.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):45-54 [10227724.001]
  • [Cites] Cancer Lett. 1999 Jul 19;142(1):121-7 [10424790.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):466-9 [10502721.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2240-5 [10521973.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):398-403 [15816444.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] Biosci Rep. 1999 Oct;19(5):473-83 [10763814.001]
  • [Cites] Clin Biochem. 2000 Apr;33(3):167-73 [10913513.001]
  • [Cites] Tumour Biol. 1996;17(3):176-92 [8638091.001]
  • (PMID = 16188033.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL34012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC5B protein, human; 0 / MUC8 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-5B; 0 / Mucins; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC1249559
  •  go-up   go-down


42. Mood NI, Eftekhar Z, Haratian A, Saeedi L, Rahimi-Moghaddam P, Yarandi F: A cytohistologic study of atypical glandular cells detected in cervical smears during cervical screening tests in Iran. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):257-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cytohistologic study of atypical glandular cells detected in cervical smears during cervical screening tests in Iran.
  • Among them were cervical intraepithelial neoplasia, basal cell abnormality of undetermined significance, cervical adenocarcinoma, endometrial hyperplasia or adenocarcinoma, vaginal adenocarcinoma, endocervical glandular dysplasia, metastatic breast carcinoma, and simple nonvillous trophoblastic tissue.
  • Therefore, presence of AGC in cervical smears may exhibit a spectrum of findings, ranging from benign/reactive changes to squamous or glandular premalignancy or malignancy.
  • The results of the current study underline the importance of follow-up for patients with the diagnosis of AGC.
  • To our knowledge, this is the first report in Iran showing the significance of AGC diagnosis.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Vaginal Smears


43. Baek KH, Lee HJ, Kim MS, Kim YS, Seong M, Lee EJ, Lee MY: Molecular cloning of rHAUSP encoding a deubiquitinating enzyme in rat testis. Oncol Rep; 2006 Jan;15(1):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The over-expression of rHAUSP induced cell death of cervical adenocarcinoma cells.


44. Movva S, Noone AM, Banerjee M, Patel DA, Schwartz K, Yee CL, Simon MS: Racial differences in cervical cancer survival in the Detroit metropolitan area. Cancer; 2008 Mar 15;112(6):1264-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial differences in cervical cancer survival in the Detroit metropolitan area.
  • BACKGROUND: African-American (AA) women have lower survival rates from cervical cancer compared with white women.
  • The objective of this study was to examine the influence of socioeconomic status (SES) and other variables on racial disparities in overall survival among women with invasive cervical cancer.
  • METHODS: One thousand thirty-six women (705 white women and 331 AA women) who were diagnosed with primary invasive cancer of the cervix between 1988 and 1992 were identified through the Metropolitan Detroit Cancer Surveillance System (MDCSS), a registry in the Surveillance, Epidemiology, and End Results (SEER) database.
  • CONCLUSIONS: In this study, factors that affected access to medical care appeared to have a more important influence than race on the long-term survival of women with invasive cervical cancer.
  • [MeSH-major] African Americans. European Continental Ancestry Group. Uterine Cervical Neoplasms / ethnology. Uterine Cervical Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / ethnology. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Carcinoma, Squamous Cell / ethnology. Carcinoma, Squamous Cell / mortality. Female. Follow-Up Studies. Humans. Michigan / epidemiology. Middle Aged. Neoplasm Invasiveness. Risk Factors. SEER Program. Socioeconomic Factors. Survival Rate

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • [Cites] Cancer Causes Control. 1999 Dec;10(6):525-37 [10616822.001]
  • [Cites] J Womens Health (Larchmt). 2006 Oct;15(8):941-51 [17087618.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):357-61 [11104605.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):869-73 [11241257.001]
  • [Cites] J Assoc Acad Minor Phys. 2000;11(4):55-9 [11852650.001]
  • [Cites] Am J Public Health. 2002 Jul;92(7):1100-2 [12084688.001]
  • [Cites] Am J Epidemiol. 2002 Sep 1;156(5):471-82 [12196317.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):333-9 [12648583.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Am J Public Health. 2003 Oct;93(10):1655-71 [14534218.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):395-401 [14599872.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):495-501 [15297194.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1051-7 [15329915.001]
  • [Cites] Br Med J (Clin Res Ed). 1988 Feb 6;296(6619):386-91 [3125911.001]
  • [Cites] J Epidemiol Community Health. 1990 Dec;44(4):293-6 [2277250.001]
  • [Cites] Am J Public Health. 1991 May;81(5):646-9 [2014871.001]
  • [Cites] Am J Epidemiol. 1991 Apr 1;133(7):672-82 [2018022.001]
  • [Cites] J Ark Med Soc. 1992 Jul;89(2):79-83 [1629111.001]
  • [Cites] Ethn Dis. 1992 Winter;2(1):47-54 [1458215.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):31-46 [8115784.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2838-42 [8194025.001]
  • [Cites] Am J Public Health. 1994 Jun;84(6):1007-9 [8203665.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2518-23 [8625079.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):1934-47 [8634985.001]
  • [Cites] Epidemiology. 1996 Sep;7(5):517-20 [8862984.001]
  • [Cites] Obstet Gynecol. 1996 Dec;88(6):914-8 [8942827.001]
  • [Cites] Ethn Health. 1996 Mar;1(1):65-75 [9395549.001]
  • [Cites] Med Care. 1997 Dec;35(12):1220-4 [9413310.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):151-8 [9826453.001]
  • [Cites] Am J Epidemiol. 1998 Dec 15;148(12):1184-6 [9867264.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jun;180(6 Pt 1):1464-7 [10368490.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):113-7 [10502436.001]
  • [Cites] Obstet Gynecol. 1999 Oct;94(4):509-15 [10511350.001]
  • [Cites] Am J Public Health. 2004 Dec;94(12):2098-103 [15569960.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):550-8 [15863159.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):432-6 [16137753.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4):713-9 [16259498.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):278-84 [16434087.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):443-50 [10802372.001]
  • (PMID = 18257090.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / T32 CA083654
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS515502; NLM/ PMC3799770
  •  go-up   go-down


45. Chan KK, Ip P, Kwong P, Tam KF, Ngan HY: A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix. Int J Gynecol Cancer; 2008 May-Jun;18(3):559-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix.
  • Clear cell adenocarcinoma of the cervix (CCAC) is an uncommon tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Neoplasm Invasiveness / pathology. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692092.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Manfredi R, Gui B, Giovanzana A, Marini S, Di Stefano M, Zannoni G, Scambia G, Bonomo L: Localized cervical cancer (stage &lt;IIB): accuracy of MR imaging in planning less extensive surgery. Radiol Med; 2009 Sep;114(6):960-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized cervical cancer (stage <IIB): accuracy of MR imaging in planning less extensive surgery.
  • PURPOSE: This study was undertaken to determine the accuracy of magnetic resonance (MR) imaging in the preoperative staging of patients with clinically localised cervical cancer eligible for less extensive surgery.
  • MATERIALS AND METHODS: Fifty-three patients with biopsy-proven carcinoma of the uterine cervix and eligible for conservative surgery prospectively underwent MR imaging.
  • Images were assessed for tumour site and size, infiltration of the cervical stroma, infiltration of vaginal fornices and relationship between the tumour and the internal os of the endocervical canal and the presence and dimensions of pelvic and lumboaortic lymph nodes (cutoff values 1 cm and 0.5 cm minimum axial diameter).
  • RESULTS: The endocervix was the site of origin of 25% (13/53) of the cervical tumours and the exocervix the site of origin of 75% (40/53).
  • In the assessment of cervical stroma infiltration, there was agreement between MR imaging and histopathology in 75% of cases.
  • CONCLUSIONS: MR imaging had a high level of accuracy in the preoperative assessment of the extent of cervical tumour in patients eligible for conservative surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / pathology


47. Niwa T, Yoshida T, Doiuchi T, Ito K, Nakayama H, Odagiri K, Inoue T: Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy. Br J Radiol; 2008 Aug;81(968):659-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
  • We retrospectively assessed the factors that may impede tumour reduction of locally advanced cervical adenocarcinoma treated with balloon-occluded arterial infusion chemotherapy (BOAI) as initial therapy.
  • BOAI was performed via uterine arteries in 21 patients, and via the anterior division or main trunk of the internal iliac artery (when the uterine arteries were obscured) in 10 patients.
  • Internal iliac arterial infusion significantly correlated with "no response" compared with uterine arterial infusion (p<0.001).
  • These data suggest that uterine arteries being obscured to arterial infusion may be associated with a poor response to BOAI for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628334.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Shimada M, Kigawa J, Nishimura R, Yamaguchi S, Kuzuya K, Nakanishi T, Suzuki M, Kita T, Iwasaka T, Terakawa N: Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol; 2006 May;101(2):234-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastasis in carcinoma of the uterine cervix.
  • BACKGROUND: The present study was conducted to determine the frequency and clinicopathological features of ovarian metastasis in a large population of patients with stage Ib-IIb cervical cancer.
  • METHODS: The study population consisted of 3471 patients with stage Ib to IIb cervical cancer who underwent radical hysterectomy, including pelvic lymphadenectomy and bilateral salpingo-oophorectomy, at our six institutions between 1981 and 2000.
  • To our knowledge, this study is the largest review of patients with ovarian metastasis from cervical cancer.
  • The incidence of ovarian metastasis in patients with cervical cancer was 0.22% for stage Ib, 0.75% for stage IIa, and 2.17% for stage IIb with squamous cell carcinoma, and 3.72%, 5.26%, and 9.85%, respectively, in adenocarcinoma.
  • Ovarian metastasis occurred more frequently among patients with adenocarcinoma than among those with squamous cell carcinoma (5.31% vs. 0.79%).
  • CONCLUSION: Study results indicate that ovaries can be preserved in patients with stage Ib-IIa squamous cell carcinoma but removed in all patients with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


49. Bazhenov AG, Guseĭnov KD, Khadzhimba AV, Baranov SB, Il'iashenko SA, Maksimov SIa: [Results of treatment for recurrent cancer of the uterine cervix]. Vopr Onkol; 2009;55(3):319-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of treatment for recurrent cancer of the uterine cervix].
  • The investigation involved 285 patients suffering from recurrences and distant metastases of uterine carcinoma cases of 24% of all (primary tumor).
  • Local recurrence rate for primary squamous cell tumor was 53.6%, adenocarcinoma - 6.3% and poorly-differentiated cell carcinoma - 4.9%.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / therapy. Neoplasm Recurrence, Local / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Female. Humans. Intestinal Neoplasms / secondary. Intestinal Neoplasms / therapy. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome. Urologic Neoplasms / secondary. Urologic Neoplasms / therapy


50. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK: Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol; 2005 Nov;99(2):415-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
  • OBJECTIVE: To investigate prognostic significance of and correlations between HER1 (EGFR), HER2 (c-erb-B2), HER3 (c-erb-B3), HER4 (c-erb-B4), and phosphorylated Akt (P-Akt) in patients treated with radiation for cervical carcinoma.
  • METHODS: Fifty-five patients with stages I-IVA cervical carcinoma were treated with definitive radiotherapy.
  • These data emphasize the importance of continued basic and translational research on the HER family of receptors in cervical carcinoma.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Uterine Cervical Neoplasms / enzymology. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Disease-Free Survival. Female. Humans. Multivariate Analysis. Neoplasm Staging. Phosphorylation. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Receptor, ErbB-4. Treatment Outcome


51. Baalbergen A, Veenstra Y, Stalpers LL, Ansink AC: Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev; 2010;(1):CD006248
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary surgery versus primary radiation therapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.
  • BACKGROUND: For early squamous cell carcinoma of the uterine cervix, the outcome is similar after either primary surgery or primary radiotherapy.
  • There are reports that this is not the case for early adenocarcinoma (AC) of the uterine cervix: some studies have reported that the outcome is better after primary surgery.
  • There are no systematic reviews about surgery versus chemoradiation in the treatment of cervical cancer.
  • OBJECTIVES: The objectives of this review were to compare the effectiveness and safety of primary surgery for early stage AC of the uterine cervix with primary radiotherapy or chemoradiation.
  • SELECTION CRITERIA: Studies of treatment of patients with early AC of the uterine cervix were included.
  • MAIN RESULTS: Analysis of a subgroup of one RCT showed that surgery for early cervical AC was better than RT.
  • AUTHORS' CONCLUSIONS: We recommend surgery for early stage AC of the uterine cervix in carefully staged patients.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery


52. Sauder K, Wilbur DC, Duska L, Tambouret RH: An approach to post-radical trachelectomy vaginal-isthmus cytology. Diagn Cytopathol; 2009 Jun;37(6):437-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical trachelectomy (RT) is the surgical amputation of the uterine cervix with paracervical lymphadenectomy, performed in reproductive age women to treat invasive squamous-cell carcinoma or endocervical adenocarcinoma while preserving the uterine corpus for potential child bearing.
  • Fifty-four post-RT vaginal-isthmic cytology specimens were reviewed from nine patients, seven with adenocarcinoma, and two with squamous-cell carcinoma.
  • The cytology specimens most often interpreted as AGC contained many groups of hyperchromatic crowded glandular cells and/or stromal cells derived from direct sampling of the lower uterine segment.
  • In particular, a primary diagnosis of adenocarcinoma makes differentiating benign reactive glandular cells from recurrence a critical issue.
  • [MeSH-major] Cervix Uteri / surgery. Cytological Techniques / methods. Vagina / pathology

  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19217064.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Wani Y, Notohara K, Tsukayama C: Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature. Int J Gynecol Pathol; 2008 Jul;27(3):346-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature.
  • Mesonephric adenocarcinoma (MA) is a rare tumor of the female genital tract, mainly in the cervix and vagina, which is usually associated with mesonephric remnants or mesonephric hyperplasia.
  • Here, we report a rare case of MA of the uterine corpus.
  • Abdominal computed tomography scan confirmed a uterine tumor measuring 8.6 cm.
  • The tumor was confined to the myometrium and showed strong resemblance to cervical MA despite the absence of mesonephric hyperplasia or remnants.
  • In addition, the ductal pattern simulating endometrioid adenocarcinoma was also noted.
  • Other elements consisted of a retiform pattern, serous adenocarcinoma-like papillary budding, and glomeruloid morphology.
  • We review the previously published cases of MA and discuss the principal differential diagnosis of MA in the uterine corpus.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580312.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


54. Choi JS, Shin S, Jin YH, Yim H, Koo KT, Chun KH, Oh YT, Lee WH, Lee SK: Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis; 2007 Jul;12(7):1229-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have suggested that upregulation of Cyclin A-dependent protein kinase 2 (Cdk2) activity is an essential event in apoptotic progression and the mitochondrial permeability transition in human cancer cells.
  • Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252195.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / bcl-2-Associated X Protein; 6PLQ3CP4P3 / Etoposide; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


55. Bilton R, Mazure N, Trottier E, Hattab M, Déry MA, Richard DE, Pouysségur J, Brahimi-Horn MC: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem; 2005 Sep 2;280(35):31132-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we show that the ARD1 mRNA and protein levels are not regulated by hypoxia in several human tumor cell lines, including cervical adenocarcinoma HeLa cells, fibrosarcoma HT1080 cells, adenovirus-transformed human kidney HEK293 cells, and human breast cancer MCF-7 cells.

  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Biol Chem. 2006 Jun 2;281(22):15592
  • (PMID = 15994306.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / HIF1A protein, human; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / endothelial PAS domain-containing protein 1; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  •  go-up   go-down


56. Djordjevic B, Clement-Kruzel S, Atkinson NE, Malpica A: Nodal endosalpingiosis in ovarian serous tumors of low malignant potential with lymph node involvement: a case for a precursor lesion. Am J Surg Pathol; 2010 Oct;34(10):1442-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We first examined the frequency of nodal endosalpingiosis in 30 OSLMP cases, 30 cervical adenocarcinoma cases, and 30 endometrial endometrioid adenocarcinoma cases.
  • The rate of nodal endosalpingiosis was significantly higher in OSLMP cases (33%) compared with both cervical (0%, P<0.0001) and endometrial tumor cases (3%, P=0.0015).
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871218.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Martínez-Palones JM, Gil-Moreno A, Pérez-Benavente MA, Garcia-Giménez A, Xercavins J: Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis? Gynecol Oncol; 2005 Apr;97(1):292-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis?
  • BACKGROUND: We present a case of umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer.
  • CASE: A 59-year-old woman with stage IIIB cervical adenocarcinoma underwent laparoscopic paraaortic lymphadenectomy as well as a conventional laparoscopy to assess the presence of peritoneal carcinomatosis.
  • Seven months after completion of chemoradiotherapy, the patient presented a 2.5-cm umbilical tumor involving the trocar tract together with recurrence of the cervical mass.
  • Histological examination of the excised umbilical mass showed recurrence of the cervical adenocarcinoma, with strong peritumoral CD31 immunocytochemical expression.
  • [MeSH-major] Abdominal Neoplasms / secondary. Adenocarcinoma / secondary. Neoplasm Seeding. Umbilicus / pathology. Uterine Cervical Neoplasms / pathology


58. Háznagy-Radnai E, Réthy B, Czigle S, Zupkó I, Wéber E, Martinek T, Falkay G, Máthé I: Cytotoxic activities of Stachys species. Fitoterapia; 2008 Dec;79(7-8):595-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activity of Stachys plants and of aucubin and harpagide against MCF7-breast adenocarcinoma, HeLa-cervix adenocarcinoma, A431-skin carcinoma of epithelial origin is reported in this study.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672034.001).
  • [ISSN] 1873-6971
  • [Journal-full-title] Fitoterapia
  • [ISO-abbreviation] Fitoterapia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cytotoxins; 0 / Glucosides; 0 / Iridoid Glucosides; 0 / Iridoid Glycosides; 0 / Iridoids; 0 / Plant Extracts; 0 / Pyrans; 2G52GS8UML / aucubin; 6926-08-5 / harpagide
  •  go-up   go-down


59. Yang Y, Chen L, Han BS, Xu CM, Pan HZ: [Construction and expression of various human prion proteins mutants with modified N-glycosylation sites in mammalian cells]. Sheng Wu Gong Cheng Xue Bao; 2006 May;22(3):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the biological function of the N-glycosylation modification of prion proteins (PrP), various eukaryotic expression vectors for the mutants with N-glycosylation modification of human PrP had been constructed and expressed.
  • With site-direct mutation technique, human PRNP gene was mutated and the obtained mutants were subcloned into eukaryotic expressing plasmid pcDNA3.1 and transiently expressed in Hela cervical adenocarcinoma cell.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755913.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 0 / Mutant Proteins; 0 / Prions
  •  go-up   go-down


60. Yuan YV, Walsh NA: Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food Chem Toxicol; 2006 Jul;44(7):1144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary Laminaria and Porphyra sp. have been reported to reduce the risk of intestinal or mammary cancer in animal studies.
  • Thus, in the present study, we evaluated the effect of red alga, dulse (Palmaria palmata) and three kelp (Laminaria setchellii, Macrocystis integrifolia, Nereocystis leutkeana) extracts on human cervical adenocarcinoma cell line (HeLa cells) proliferation using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554116.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


61. Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D: Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med; 2006 Oct;130(10):1510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.
  • OBJECTIVE: To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions.
  • DESIGN: Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix.
  • Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix.
  • MUC2 staining was noted in 25%, 40%, and 22% of AIS, endocervical adenocarcinomas, and endometrial adenocarcinomas, respectively.
  • About 38% of AIS, 75% of endocervical adenocarcinomas, and 44% of endometrial adenocarcinomas expressed MUC4.
  • Half of AIS, most of endocervical adenocarcinomas, and 22% of endometrial adenocarcinomas expressed MUC5AC.
  • These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucins / metabolism. Uterine Cervical Diseases / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


62. Eitan R, Levavi H, Peled Y, Brenner R, Sabah G, Ben-Arie A, Dgani R, Fishman A, Sulkes A, Fenig E, Koren C: Should simple hysterectomy be added after chemo-radiation for stage IB2 and bulky IIA cervical carcinoma? Aust N Z J Obstet Gynaecol; 2010 Jun;50(3):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should simple hysterectomy be added after chemo-radiation for stage IB2 and bulky IIA cervical carcinoma?
  • BACKGROUND AND AIMS: Management of bulky cervical tumours is controversial.
  • We describe the addition of high dose rate brachytherapy with concomitant chemotherapy to an attenuated protocol of radiation followed by simple hysterectomy in the management of bulky cervical tumours.
  • METHODS: Between January, 2003 and December, 2006, 23 patients diagnosed with bulky cervical tumours underwent a fixed chemo-radiation protocol followed by simple hysterectomy.
  • On final pathology, 12 patients (52%) had a pathological complete response, whereas 11 patients (48%) had residual carcinoma in the cervix.
  • CONCLUSIONS: This attenuated protocol of chemo-radiation using HDR brachytherapy followed by simple hysterectomy is a viable option in the treatment of bulky cervical carcinomas.
  • The rate of residual cervical disease after chemo-radiation is substantial, but simple hysterectomy achieved negative surgical margins in all cases.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy. Uterine Cervical Neoplasms / surgery


63. Choi SJ, Brylev KA, Xu JZ, Mironov YV, Fedorov VE, Sohn YS, Kim SJ, Choy JH: Cellular uptake and cytotoxicity of octahedral rhenium cluster complexes. J Inorg Biochem; 2008 Nov;102(11):1991-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular uptake behavior of a novel class of octahedral rhenium cluster compounds, hexahydroxo complexes K(4)[{Re(6)S(8)}(OH)(6)].8H(2)O (1) and K(4)[{Re(6)Se(8)}(OH)(6)].8H(2)O (2), was evaluated in human cervical adenocarcinoma HeLa cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783832.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Organometallic Compounds; 7440-15-5 / Rhenium
  •  go-up   go-down


64. Xue LY, Zou SM, Zheng S, Xie YQ, Wen P, Liu XY, Lin DM, Lü N: [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Zhonghua Zhong Liu Za Zhi; 2010 Nov;32(11):838-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance].
  • OBJECTIVE: To investigate and analyze the expression of fascin and CK14 in multiple histological types of cancer and to explore the potential value of the two proteins as markers in diagnosis and differential diagnosis of various cancer types.
  • METHODS: Tissue microarray containing esophageal squamous cell carcinoma (SCC), lung SCC, larynx SCC, uterine cervical SCC, SCC of external genital organs, lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, heptocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating ductal carcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, 30 cases each, as well as corresponding normal controls was constructed.
  • RESULTS: In normal esophagus, bronchus, larynx, uterine cervix and skin, fascin was mainly expressed in the basal cells or reserve cells, but the expression was diffuse in esophageal SCC, lung SCC, larynx SCC, uterine cervical SCC and SCC of external genital organs, with a positive rate of 90.0%, 90.0%, 96.7%, 78.6% and 89.7%, respectively.
  • In the normal tissue of other organs, except breast and uterine endometrium, fascin was negative.
  • In lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, the positive rates were 38.0%, 23.3%, 14.3%, 10.3%, 73.3%, 13.3%, 6.7%, 60.0%, 66.7% and 10.0%, respectively.
  • The positive rates of CK14 were 76.7%, 36.7%, 83.3%, 60.7% and 96.3% in esophageal SCC, lung SCC, larynx SCC, uterine cervical SCC and SCC of external genital organs, respectively.
  • It was weak and focal in lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma, and renal clear cell carcinoma, with a positive rate of 13.3%, 13.3%, 20.7%, 41.4%, 46.7%, 6.7%, 40.0%, 13.3%, 20.0% and 6.7%, respectively.
  • Combination of fascin and CK14 should be a valuable marker in diagnosis and differential diagnosis of carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Keratin-14 / metabolism. Laryngeal Neoplasms / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223690.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Keratin-14; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


65. Lee EJ, Mcclelland M, Wang Y, Long F, Choi SH, Lee JH: Distinct DNA methylation profiles between adenocarcinoma and squamous cell carcinoma of human uterine cervix. Oncol Res; 2010;18(9):401-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct DNA methylation profiles between adenocarcinoma and squamous cell carcinoma of human uterine cervix.
  • The big limitation in cervical cancer research is that it is too hard to obtain the pure normal tissue from a cervical cancer mass.
  • So, we first profile type-specific DNA methylation of major two types of human uterine cervical cancer, adenocarcinoma (ACA) and squamous cell carcinoma (SCC), to establish a precise source of marker research.
  • To assess the DNA methylation status of promoter regions in human uterine cervical ACAs and SCCs, fresh frozen tissues were obtained from bulky tumor masses to minimize the contamination from normal tissues and two array platforms using digestion with methylation-sensitive restriction-enzyme HpaII, ligation, and PCR were performed: an array of 11,994 (approximately 1.5 kb) PCR products from 10,445 promoter regions, and an array of 355,264 oligonucleotides for 18,212 HpaII fragments in 12,617 promoter regions.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. DNA Methylation. Gene Expression Profiling. Uterine Cervical Neoplasms / genetics


66. Peregrin-Alvarez I, Akl MN, Morrow CP, Magrina JF: Metastatic and recurrent adenocarcinoma of the uterine cervix: a long-term survival of 16 years. Eur J Gynaecol Oncol; 2010;31(3):333-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic and recurrent adenocarcinoma of the uterine cervix: a long-term survival of 16 years.
  • PURPOSE OF INVESTIGATION: Recurrent metastatic adenocarcinoma of the cervix is associated with an extremely poor prognosis.
  • CASE REPORT: We report a case of a 43-year-old patient with Stage IB adenocarcinoma of the cervix.
  • CONCLUSION: We conclude that long-term multi-modal salvage treatment may achieve longer survival in rare cases with recurrent metastatic adenocarcinoma of the cervix.
  • [MeSH-major] Adenocarcinoma / therapy. Neoplasm Recurrence, Local / therapy. Uterine Cervical Neoplasms / therapy


67. Pukkala E, Malila N, Hakama M: Socioeconomic differences in incidence of cervical cancer in Finland by cell type. Acta Oncol; 2010;49(2):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic differences in incidence of cervical cancer in Finland by cell type.
  • INTRODUCTION: We studied variation in incidence of cervix cancer during 1971-1995 among Finnish women born in 1906 to 1945 by social class and cell type.
  • MATERIAL AND METHODS: The Finnish Cancer Registry data were linked to the 1970 Population Census, which included social class data.
  • There were 0.8 million individuals in the cohort under follow-up, with 5,102 squamous cell cancers and 573 cases of cervical adenocarcinoma diagnosed after the census date.
  • RESULTS: Incidence of squamous cell cancer was more than two-fold in the lowest social class (standardized incidence ratio (SIR) 1.29, 95% CI 1.21-1.36) as compared with the highest one (SIR 0.59, 0.51-0.66), while there was no association between social class and risk on adenocarcinoma (SIR 1.07, 0.87-1.28 and 1.08, 0.79-1.45, respectively).
  • DISCUSSION: Oncogenic HPV is regarded as the necessary cause of all types of cervix cancer.
  • Lack of association between adenocarcinoma and social class makes the HPV-etiology of this cell type less credible than that of squamous cell cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology


68. Cheeti S, Lee CH: The involvement of intracellular calcium in the MCT-mediated uptake of lactic acid by HeLa cells. Mol Pharm; 2010 Feb 1;7(1):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The changes in intracellular pH (pH(in)) and MCT mediated uptake rates of L-lactic acid by HeLa cells, a human cervical adenocarcinoma cell line, were evaluated under the conditions, whose [Ca2+](in) concentrations were altered by various calcium modulators, such as EGTA-AM (a chelator), nifedipine (a Ca2+ channel antagonist) and A23187 (an ionophore).
  • An understanding of the role of [Ca2+](in) in the MCT mediated transport process could provide an efficient strategy to improve the systemic delivery of monocarboxylate substrates through the cervical mucosa.

  • Hazardous Substances Data Bank. Nifedipine .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 1992 Nov;36(11):2462-7 [1489189.001]
  • [Cites] Endocrinology. 1992 Sep;131(3):1125-33 [1324151.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 18;1275(1-2):127-32 [8688445.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):929-39 [8743940.001]
  • [Cites] Tohoku J Exp Med. 1996 Aug;179(4):291-4 [8944431.001]
  • [Cites] Biochem J. 1998 Jan 15;329 ( Pt 2):321-8 [9425115.001]
  • [Cites] J Am Coll Cardiol. 1999 Jan;33(1):242-9 [9935037.001]
  • [Cites] BJOG. 2005 Jun;112(6):754-8 [15924532.001]
  • [Cites] Int J Pharm. 2006 Nov 15;325(1-2):48-54 [16887304.001]
  • [Cites] Blood. 2007 May 1;109(9):3812-9 [17255361.001]
  • [Cites] Mol Cell Biochem. 2008 Mar;310(1-2):191-201 [18095144.001]
  • [Cites] BJU Int. 2008 Jun;101 Suppl 4:8-15 [18430116.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 2000;17(5):509-55 [11108158.001]
  • [Cites] Reprod Fertil Dev. 2000;12(3-4):201-7 [11302430.001]
  • [Cites] Am J Obstet Gynecol. 2001 Aug;185(2):375-9 [11518895.001]
  • [Cites] Antimicrob Agents Chemother. 2002 May;46(5):1375-80 [11959571.001]
  • [Cites] FEBS Lett. 2002 Jun 19;521(1-3):205-10 [12067706.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Dec;285(6):C1527-36 [12954600.001]
  • [Cites] Annu Rev Biochem. 1976;45:501-30 [786156.001]
  • [Cites] J Biol Chem. 1987 Jan 15;262(2):649-53 [3027061.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):123-7 [1309603.001]
  • [Cites] Biochem J. 1995 Nov 15;312 ( Pt 1):293-300 [7492327.001]
  • (PMID = 19905008.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD040784-01; United States / NICHD NIH HHS / HD / R15 HD040784; United States / NICHD NIH HHS / HD / HD 40784-01; United States / NICHD NIH HHS / HD / R15 HD040784-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Chelating Agents; 0 / DNA Primers; 0 / Ionophores; 0 / Monocarboxylic Acid Transporters; 0 / RNA, Messenger; 0 / Sodium-Hydrogen Antiporter; 0 / Symporters; 0 / monocarboxylate transport protein 1; 33X04XA5AT / Lactic Acid; 37H9VM9WZL / Calcimycin; 526U7A2651 / Egtazic Acid; 99590-86-0 / EGTA acetoxymethyl ester; 9NEZ333N27 / Sodium; I9ZF7L6G2L / Nifedipine; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS159719; NLM/ PMC2815175
  •  go-up   go-down


69. Pak SC, Martens M, Bekkers R, Crandon AJ, Land R, Nicklin JL, Perrin LC, Obermair A: Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol; 2007 Dec;47(6):504-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix.
  • BACKGROUND: Since the introduction of the Pap smear screening, the incidence of squamous cell carcinoma (SCC) has decreased significantly, but the incidence of adenocarcinoma (AC) relative to SCC has increased.
  • AIM: To compare the Pap smear history of patients with AC and SCC of the cervix.
  • METHODS: Patients for the study were identified from the database of Queensland Centre for Gynaecological Cancer.
  • Patients with AC and SCC were matched for age at diagnosis and International Federation of Gynecology and Obstetrics stage.
  • Data were collected upon the histological type of cancer, result of the most recent Pap smear, date and result of the Pap smear prior to the most recent Pap smear and symptoms.
  • The time between the most recent Pap smear and the diagnosis of cervical cancer was significantly shorter for patients with AC (P=0.01).
  • Thus, Pap smear prior to a diagnosis of AC is more likely than SCC false-negative and therefore not indicative of cervical cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Papanicolaou Test. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears / utilization


70. Hope AJ, Saha P, Grigsby PW: FDG-PET in carcinoma of the uterine cervix with endometrial extension. Cancer; 2006 Jan 1;106(1):196-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in carcinoma of the uterine cervix with endometrial extension.
  • BACKGROUND: The authors wished to determine whether pretreatment pathologic evidence of endometrial invasion correlated with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings and outcomes in patients with carcinoma of the uterine cervix.
  • METHODS: Pretreatment whole body FDG-PET was performed in 58 patients with cervical carcinoma who also underwent pathologic evaluation of the endometrium by biopsy or dilation and curettage.
  • CONCLUSIONS: Endometrial extension in cervical cancer correlated strongly with risk of FDG-PET detected lymph node metastases in this study's population and was associated with a poor prognosis.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Neuroendocrine / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Endometrial Neoplasms / radionuclide imaging. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radionuclide imaging. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Cervix Uteri / pathology. Cervix Uteri / radionuclide imaging. Combined Modality Therapy. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Positron-Emission Tomography. Prospective Studies. Radiopharmaceuticals. Treatment Outcome


71. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol; 2006 Mar;107(3):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of atypical glandular cells on cervical cytology.
  • These data showed the following rates of pathology: 8.5% low-grade squamous intraepithelial lesions (LSIL), 11.1% high-grade squamous intraepithelial lesions (HSIL), 2.9% adenocarcinoma in situ, 1.4% endometrial hyperplasia, and 5.2% malignancy.
  • The most common malignancies were endometrial adenocarcinoma (57.6%), cervical adenocarcinoma (23.6%), ovarian and fallopian tube carcinoma (6.4%), squamous cell carcinoma of the cervix (5.4%), and other (6.9%).
  • CONCLUSION: Histologic diagnosis showed that 29.0% of these Pap tests had findings requiring follow-up or therapeutic intervention, including a 5.2% rate of malignancy.
  • Based on these findings, 99.6% of the diagnoses are within the region of surveillance when AGUS Pap tests are evaluated with colposcopy and directed biopsy, endocervical curettage, an endometrial biopsy in patients with risk factors for endometrial cancer, and pelvic examination.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Hyperplasia / pathology. Uterine Cervical Neoplasms / pathology


72. Chuang LT, Lerner DL, Liu CS, Nezhat FR: Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer.
  • A combined pelvic lymphadenectomy with radical vaginal trachelectomy is an alternative to radical hysterectomy in the treatment of young women with cervical cancer desiring fertility preservation.
  • A 30-year-old woman, gravida 1, para 1, desiring fertility preservation was given the diagnosis of invasive adenocarcinoma on cervical cone excision.
  • We hope robotic-assisted radical trachelectomy will become an option for select women with early-stage cervical cancer who desire fertility preservation.
  • [MeSH-major] Adenocarcinoma / surgery. Fertility / physiology. Lymph Node Excision / methods. Robotics. Uterine Cervical Neoplasms / surgery


73. Lee JW, Park JA, Kim SH, Seo JH, Lim KJ, Jeong JW, Jeong CH, Chun KH, Lee SK, Kwon YG, Kim KW: Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia. Cancer Sci; 2007 Sep;98(9):1476-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present article protein kinase C-delta (PKC-delta) is activated by hypoxia, increases the protein stability and transcriptional activity of HIF-1alpha in human cervical adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608772.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 2.7.11.13 / Protein Kinase C-delta
  •  go-up   go-down


74. Sato H, Nanjo H, Tanaka H, Tanaka T: Arias-Stella reaction in an adenomyomatous polyp of the uterus. Acta Obstet Gynecol Scand; 2007;86(1):106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 33-year-old Japanese woman, gravida 1, para 1, presented for an initial prenatal examination at 6-week gestation; ultrasound revealed a myoma-like solid mass in the cervical canal.
  • An abnormal Papanicolaou's smear (highly suspicious of adenocarcinoma) prompted the resection of this pedunculated polyp.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervix Uteri / cytology. Pregnancy Complications, Neoplastic / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Trimester, First. Vaginal Smears


75. Pradhan D, Pattnaik K, Pahi J, Mohanty P, Satpathy S, Behuria S: Adenoid cystic carcinoma in the uterine cervix: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):1039-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma in the uterine cervix: a case report.
  • BACKGROUND: Adenoid cystic carcinoma, a variant of adenocarcinoma of the uterine cervix, is an extremely rare neoplasm.
  • This report describes a case of primary adenoid cystic carcinoma of the uterine cervix and includes the cytopathologic and histopathologic findings.
  • Speculum examination showed a firm mass in the uterine cervix.
  • The diagnosis of adenoid cystic carcinoma was confirmed by the histopathologic examination of the biopsy specimen as well as the excised specimen, which characteristically revealed the presence of a cribriform pattern of the tumor cells.
  • CONCLUSION: We reported a case of a rare and unusual variant of adenocarcinoma of the uterine cervix by considering the characteristic cytologic features of the globules of pale, translucent material surrounded by halos of cells in cribriform adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


76. Roy D, Kulkarni A, Kulkarni S, Thakur MH, Maheshwari A, Tongaonkar HB: Transrectal ultrasound-guided biopsy of recurrent cervical carcinoma. Br J Radiol; 2008 Nov;81(971):902-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transrectal ultrasound-guided biopsy of recurrent cervical carcinoma.
  • The objective of this study was to evaluate the feasibility, safety and diagnostic accuracy of transrectal ultrasound (TRUS)-guided core biopsy for recurrent carcinoma of the uterine cervix in patients with non-diagnostic vaginal cytology and transvaginal punch biopsy.17 patients with clinical and imaging suspicion of recurrent carcinoma of the cervix, and with negative cytology and punch biopsy, were referred for TRUS-guided biopsy of a recurrent mass.
  • Data were collected with respect to demography, previous diagnosis, treatment received, size and location of the recurrent lesion, and biopsy results.
  • TRUS-guided biopsy was technically successful in all of the patients and provided histological diagnosis of recurrence in 16 patients.
  • In conclusion, TRUS-guided biopsy for recurrent cervical cancer is a feasible, safe and accurate method for establishing a histopathological diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Carcinoma, Small Cell / pathology. Cervix Uteri / pathology. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology


77. Kasamatsu T, Onda T, Sasajima Y, Kato T, Ikeda S, Ishikawa M, Tsuda H: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol; 2009 Dec;115(3):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix.
  • OBJECTIVE: A retrospective analysis was carried out to evaluate the prognostic significance of peritoneal cytology in cervical adenocarcinoma.
  • METHODS: The records of 107 patients with FIGO stage IB to IIB cervical adenocarcinoma who underwent hysterectomy were reviewed.
  • Cox model analysis revealed positive cytology [hazards ratio (HR) 6.27, 95% confidence interval (CI) 2.13-18.41], positive lymph node (HR 6.20, 95% CI 1.87-20.57), ovarian metastasis (HR 5.20, 95% CI 1.18-22.82), and histological grade (HR 5.97, 95% CI 2.00-17.78) to be independent adverse risk factors for survival among the factors analyzed (lymph node status, lymph-vascular space invasion, tumor size, depth in cervical wall, pathological parametrial involvement, infiltration to vagina, ovarian metastasis, and histological grade).
  • CONCLUSION: The presence of positive peritoneal cytology appears to be an independent prognostic risk factor in patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Cavity / pathology. Uterine Cervical Neoplasms / pathology


78. Kovács A, Vasas A, Forgo P, Réthy B, Zupkó I, Hohmann J: Xanthanolides with antitumour activity from Xanthium italicum. Z Naturforsch C; 2009 May-Jun;64(5-6):343-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The isolated compounds 1-4 were evaluated for their antiproliferative activities, and were demonstrated to exert significant cell growth inhibitory activity against human cervix adenocarcinoma (HeLa), skin carcinoma (A431), and breast adenocarcinoma (MCF7) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678536.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


79. Jung YW, Kim SW, Kim S, Kim JH, Cho NH, Kim JW, Kim YT: Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma. Eur J Obstet Gynecol Reprod Biol; 2010 Jan;148(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
  • OBJECTIVE: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy.
  • STUDY DESIGN: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study.
  • COX-2 expression was associated with poor response to treatment and cancer-related death (P=0.043 and 0.012, respectively).
  • CONCLUSION: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma.
  • However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclooxygenase 1 / biosynthesis. Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836124.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


80. Numnum TM, Makhija S, Lu B, Wang M, Rivera A, Stoff-Khalili M, Alvarez RD, Zhu ZB, Curiel DT: Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol; 2008 Jan;108(1):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hec1 (Highly Expressed in Cancer gene 1) has recently been shown to play an important role in the proper segregation of chromosomes during mitosis.
  • Recently, an adenovirus delivery system carrying RNA interference (RNAi) of Hec1 has been reported in a cervical adenocarcinoma model.
  • METHODS: Two adenoviruses (Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3), along with a negative control (Ad-siRNA-GAPDH.F5/3), were created using homologous recombination.
  • RESULTS: QPCR demonstrated a 2-log viral infectivity enhancement with Ad-siRNA-Hec1.F5/3 over Ad-siRNA-Hec1.
  • QPCR at 72 h revealed mRNA knockdown induced by Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cells, respectively (71%/60%, and 32%/78% mRNA knockdown compared to negative control).
  • Western blot revealed translational inhibition induced by both Hec1 Ads with the least knockdown seen with Ad-siRNA-GAPDH.F5/3.
  • MTS assay indicated increased cell death 8 days post-infection with Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cell lines, respectively (75% vs. 35% and 43% vs. 12% viable cells).
  • Crystal violet staining revealed increased cell death with Ad-siRNA-Hec1.F5/3 in all tested cell lines.
  • The infectivity-enhanced adenovirus as delivery mechanism shows potential application in future gene therapy models of RNAi in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2003 Sep;8(3):449-58 [12946318.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):762-8 [14599809.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4339-45 [14625284.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):162-71 [15233951.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):833-8 [15252144.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):785-95 [15350374.001]
  • [Cites] J Virol. 1968 May;2(5):430-9 [4301313.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2088-95 [12727824.001]
  • [Cites] Curr Biol. 2003 Jan 8;13(1):41-6 [12526743.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2267-70 [12351790.001]
  • [Cites] Mol Ther. 2001 Jan;3(1):28-35 [11162308.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 [7638184.001]
  • [Cites] Genes Dev. 1999 Dec 15;13(24):3191-7 [10617568.001]
  • [Cites] Gene Ther. 1997 Sep;4(9):961-8 [9349433.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):367-72 [10419055.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):341-8 [15661219.001]
  • [Cites] Mol Biol Cell. 2005 Feb;16(2):519-31 [15548592.001]
  • [Cites] Gene Ther. 2006 Jan;13(1):1-7 [16121206.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36 [16361572.001]
  • [Cites] Mol Biol Rep. 2006 Mar;33(1):43-9 [16636916.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1300-10 [16622456.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):595-603 [16865275.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1319-29 [17016667.001]
  • [Cites] Curr Oncol Rep. 2006 Nov;8(6):441-7 [17040622.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1708-13 [17106249.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1917-26 [12204675.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):275-80 [11801569.001]
  • (PMID = 18061250.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA083821-08; United States / NCI NIH HHS / CA / R01 CA083821; United States / NCI NIH HHS / CA / R01 CA083821-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NDC80 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ NIHMS38788; NLM/ PMC2744403
  •  go-up   go-down


81. Hussain SK, Sundquist J, Hemminki K: Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer; 2008 Apr 15;122(8):1873-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database.
  • Familial aggregation of cervical cancer has been demonstrated previously, however aggregation of other human papillomavirus-associated anogenital, upper aerodigestive tract and skin cancers has not been fully characterized.
  • The Swedish Family-Cancer Database, which contains reliable data on cancer incidence and nuclear family linkages for all residents of Sweden between 1958 and 2004, was used to calculate standardized incidence ratios (SIR) and 95% confidence intervals for offspring site-specific cancer risks according to site-specific cancer in sibling and parental probands.
  • Offspring cancer risk was significantly increased when either a sibling or parent was affected at the same site for penile squamous cell carcinoma (SCC, SIR = 7.54), cervical adenocarcinoma (AC, SIR = 2.31), vulvar SCC (SIR = 2.27), skin SCC (SIR = 2.14), rectal AC (SIR = 1.86), in situ cervical SCC (SIR = 1.80), invasive cervical SCC (SIR = 1.77) and upper aerodigestive tract SCC (SIR = 1.57).
  • In situ cervical SCC risk in offspring was strongly influenced by siblings affected with oropharyngeal SCC (SIR = 3.17) and tonsillar SCC (SIR = 1.84).
  • Familial skin SCC was largely unassociated with anogenital or upper aerodigestive tract cancer risk in offspring.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cluster Analysis. Family. Female. Humans. Incidence. Male. Medical Record Linkage. Middle Aged. Mouth Neoplasms / epidemiology. Odds Ratio. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Pharyngeal Neoplasms / epidemiology. Registries. Sweden / epidemiology. Tonsillar Neoplasms / epidemiology. Tumor Virus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074353.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Plummer M, Sweetland S: Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer; 2006 Mar 15;118(6):1481-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies.
  • Tobacco smoking has been classified as a cause of cervical cancer, but the effect of different patterns of smoking on risk is unclear.
  • The International Collaboration of Epidemiological Studies of Cervical Cancer has brought together and combined individual data on 13,541 women with and 23,017 women without cervical carcinoma, from 23 epidemiological studies.
  • Relative risks (RRs) and 95% confidence intervals (CIs) of carcinoma of the cervix in relation to tobacco smoking were calculated with stratification by study, age, sexual partners, age at first intercourse, oral contraceptive use and parity.
  • Current smokers had a significantly increased risk of squamous cell carcinoma of the cervix compared to never smokers (RR = 1.60 (95% CI: 1.48-1.73), p<0.001).
  • There was no association between smoking and adenocarcinoma of the cervix (RR = 0.89 (0.74-1.06) and 0.89 (0.72-1.10) for current and past smokers respectively), and the differences between the RRs for smoking and squamous cell and adenocarcinoma were statistically significant (current smoking p<0.001 and past smoking p = 0.01).
  • Eight of the studies had tested women for cervical HPV-DNA, and in analyses restricted to women who tested positive, there was a significantly increased risk in current compared to never smokers for squamous cell carcinoma (RR = 1.95 (1.43-2.65)), but not for adenocarcinoma (RR = 1.06 (0.14-7.96)).
  • In summary, smokers are at an increased risk of squamous cell but not of adenocarcinoma of the cervix.
  • [MeSH-major] Smoking / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


83. Kumar N, Bongiovanni M, Molliet MJ, Pelte MF, Egger JF, Pache JC: Diverse glandular pathologies coexist with high-grade squamous intraepithelial lesion in cyto-histological review of atypical glandular cells on ThinPrep specimens. Cytopathology; 2009 Dec;20(6):351-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To identify in cytology, high-grade squamous intraepithelial lesions with endocervical glandular extension in cases previously diagnosed as atypical glandular cells (AGC), analyse possible reasons for the diagnostic pitfall and document the frequency of glandular pathology coexisting with high-grade cervical intraepithelial lesion in histology.
  • METHODS: Thirty-nine ThinPrep cervical smear (Pap) tests reported as AGC of undetermined significance and showing high-grade lesions on histology [cervical intraepithelial neoplasia (CIN) 2 or 3, endometrial or extrauterine adenocarcinoma] were reviewed retrospectively to identify the cases of high-grade squamous intraepithelial lesion with endocervical glandular extension, using the Bethesda 2001 system.
  • RESULTS: A high frequency of diverse glandular pathologies coexisted with high-grade cervical intraepithelial lesions on histology.
  • This included endocervical glandular extension in 63%, benign glandular pathology in 33% and pre-neoplastic or malignant glandular pathology (endocervical glandular dysplasia, adenocarcinoma in situ and metastatic breast carcinoma) in 17% cases.
  • The identification of endocervical glandular extension on cervical cytology would alert the gynaecologist to perform a thorough assessment of the endocervix during colposcopy.
  • [MeSH-major] Cervical Intraepithelial Neoplasia. Cervix Uteri / pathology. Cytological Techniques. Neoplasms, Glandular and Epithelial. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Retrospective Studies. Sensitivity and Specificity. Young Adult


84. Abhishek A, Ouseph MM, Sharma P, Kamal V, Sharma M: Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case. J Med Imaging Radiat Oncol; 2008 Feb;52(1):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case.
  • Distant cutaneous metastases from cervical malignancies are uncommon, with scalp metastases being exceptional events.
  • We present the case of a 53-year-old postmenopausal lady with adenocarcinoma of the uterine cervix that metastasized to the scalp with superior sagittal sinus thrombosis 8 months after diagnosis.
  • In contrast to the seven prior cases of scalp metastases of cervical squamous cell carcinoma reported in published reports, ours is the first documentation of such an occurrence in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Head and Neck Neoplasms / secondary. Scalp / pathology. Sinus Thrombosis, Intracranial / etiology. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cervix Uteri / radiography. Cervix Uteri / surgery. Epilepsy, Tonic-Clonic / drug therapy. Epilepsy, Tonic-Clonic / etiology. Female. Humans. Hysterectomy. Magnetic Resonance Imaging / methods. Middle Aged. Tomography, X-Ray Computed / methods


85. Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B: Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res; 2010 Apr;30(4):1341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters.
  • OBJECTIVE: The expression of oestrogen and progesterone receptors in patients with adenocarcinoma of the uterine cervix was examined in order to determine their influence on prognosis and to evaluate the association between the steroid receptor expression and various clinicopathologic parameters.
  • PATIENTS AND METHODS: Oestrogen and progesterone receptor expression was investigated by immunohistochemistry from paraffin-embedded tissue in 39 patients with adenocarcinoma of the uterine cervix.
  • CONCLUSION: Oestrogen and progesterone receptors were frequently expressed in adenocarcinoma of the uterine cervix.
  • Thus, the investigation of steroid receptors adds little additional information to the clinical management and fails to play a prognostic role in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / biosynthesis. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530450.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


86. Ishioka S, Endo T, Hayashi T, Kitajima Y, Sugimura M, Sagae S, Saito T: Successful delivery after vaginal radical trachelectomy for invasive uterine cervical cancer. Int J Clin Oncol; 2006 Apr;11(2):146-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful delivery after vaginal radical trachelectomy for invasive uterine cervical cancer.
  • A 32-year-old Japanese woman was diagnosed as having stage Ib1 adenocarcinoma by diagnostic laser conization at a local hospital.
  • The excised uterine cervix and lymph nodes were pathologically negative for cancer.
  • This is the first successful case in Japan of delivery after vaginal RT for invasive uterine cervical cancer.
  • [MeSH-major] Pregnancy Outcome. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):1002-5 [14984977.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2273-9 [10590368.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1877-82 [10760765.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):614-23 [15350349.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1491-6 [9855586.001]
  • (PMID = 16622750.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


88. Ratković Z, Juranić ZD, Stanojković T, Manojlović D, Vukićević RD, Radulović N, Joksović MD: Synthesis, characterization, electrochemical studies and antitumor activity of some new chalcone analogues containing ferrocenyl pyrazole moiety. Bioorg Chem; 2010 Feb;38(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro cytotoxic activity of all the synthesized compounds was studied against cervix adenocarcinoma HeLa, melanoma Fem-x and myelogenous leukemia K562 cell lines by the MTT method.

  • Hazardous Substances Data Bank. FERROCENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19846191.001).
  • [ISSN] 1090-2120
  • [Journal-full-title] Bioorganic chemistry
  • [ISO-abbreviation] Bioorg. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferrous Compounds; 0 / Pyrazoles; 5S5A2Q39HX / Chalcone; U96PKG90JQ / ferrocene
  •  go-up   go-down


89. Yu KJ, Bashirova A, Madeleine MM, Cheng J, Johnson LG, Schwartz SM, Carrington M, Hildesheim A: Evaluation of the association with cervical cancer of polymorphisms in syndecan-1, a heparan sulfate proteoglycan involved with viral cell entry. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2504-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the association with cervical cancer of polymorphisms in syndecan-1, a heparan sulfate proteoglycan involved with viral cell entry.
  • Infection with 1 of approximately 15 oncogenic human papillomaviruses is known to be linked to the development of all histologic forms of cervical cancer.
  • We evaluated whether polymorphisms in syndecan-1 (SDC-1), a gene whose protein product is believed to be involved in human papillomavirus entry into epithelial cells, were associated with histologic subtypes of cervical cancer.
  • A total of 293 in situ/invasive adenocarcinoma cases, 260 in situ/invasive squamous cell carcinoma cases, and 478 controls from two studies conducted in the Eastern United States and Seattle area were evaluated.
  • Polymorphisms of SDC-1 were not associated with risk of squamous cell carcinomas of the cervix.
  • Similarly, there was no evidence for an association between SDC-1 exon 3 polymorphisms and risk of cervical adenocarcinomas.
  • A marginally significant increase in risk of cervical adenocarcinoma was associated with the presence of the Pro-27 polymorphism (pooled odds ratios, 1.6; 95% confidence intervals, 0.99-2.6), an effect that was restricted to the Eastern U.S. Study.
  • Our results indicate a lack of association between SDC-1 polymorphisms and risk of squamous cell carcinomas of the cervix.
  • An association between SDC-1 Pro-27 polymorphism and cervical adenocarcinoma cannot be ruled out.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006945.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112512-02; United States / NCI NIH HHS / CA / R01CA112512; United States / NCI NIH HHS / CA / R01 CA112512-02; United States / NCI NIH HHS / CA / P01CA042792; United States / NCI NIH HHS / CA / CA112512-01; United States / NCI NIH HHS / CA / CA112512-04; United States / NCI NIH HHS / CA / R01 CA112512-01; United States / NIDA NIH HHS / DA / DA 13324; United States / NCI NIH HHS / CA / R01 CA112512-03; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA112512-04; United States / NCI NIH HHS / CA / CA112512-03; United States / NCI NIH HHS / CA / CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512-05; United States / NCI NIH HHS / CA / R01 CA112512; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Syndecan-1
  •  go-up   go-down


90. Lualdi M, Colombo A, Leo E, Morelli D, Vannelli A, Battaglia L, Poiasina E, Marchesini R: Natural fluorescence spectroscopy of human blood plasma in the diagnosis of colorectal cancer: feasibility study and preliminary results. Tumori; 2007 Nov-Dec;93(6):567-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural fluorescence spectroscopy of human blood plasma in the diagnosis of colorectal cancer: feasibility study and preliminary results.
  • AIM AND BACKGROUND: Fluorescence spectroscopy of biomolecules is considered a promising method to discriminate in vivo normal tissue from malignant tissue at various sites including breast, cervix, lung, and colon.
  • In this study, the fluorescence characteristics of human blood plasma have been studied in the visible spectral range in an attempt to discriminate patients with colorectal cancer from subjects of a control population.
  • PATIENTS AND METHODS: The study involved 341 subjects, including 169 blood donors with no evidence of disease, 143 patients bearing colorectal adenocarcinomas (36 in the colon, 38 in the sigmoid colon and 69 in the rectum), 11 patients with local relapse, 10 patients with familial adenomatous polyposis and 8 with single adenomas.
  • RESULTS: The intensity of a fluorescence emission peak around 615-635 nm, which could reasonably be ascribed to endogenous porphyrins, was significantly different between patients bearing colorectal cancer and blood donors.
  • CONCLUSION: These results, although preliminary, suggest the potential of fluorescence measurements of blood plasma as an additional method for diagnostic application in colon cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Plasma. Porphyrins / blood. Spectrometry, Fluorescence
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adenomatous Polyposis Coli / diagnosis. Adult. Aged. Area Under Curve. Blood Donors. Feasibility Studies. Female. Humans. Male. Middle Aged. ROC Curve

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338491.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Porphyrins
  •  go-up   go-down


91. Van Calsteren K, Hanssens M, Moerman P, Orye G, Bielen D, Vergote I, Amant F: Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy. Acta Obstet Gynecol Scand; 2008;87(2):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy.
  • Traditionally when cervical cancer is diagnosed during the first trimester of pregnancy, oncological treatment is given priority despite the pregnant state.
  • A 32-year-old primigravida was diagnosed with invasive endocervical adenocarcinoma stage Ib1 at 8 weeks' gestation.
  • As the patient wanted to preserve the pregnancy, an amputation of the anterior cervix and retroperitoneal pelvic lymphadenectomy were performed.
  • In the absence of poor prognostic markers, we decided to adopt a conservative approach for cervical adenocarcinoma in a pregnant patient at 8 weeks' gestation.
  • [MeSH-major] Adenocarcinoma / surgery. Early Diagnosis. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Female. Humans. Lymph Node Excision. Pregnancy. Pregnancy Trimester, First


92. Zannoni GF, Vellone VG, Carbone A: Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment. Int J Gynecol Pathol; 2008 Apr;27(2):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment.
  • The introduction of radiochemotherapy for treatment of advanced cervical cancers represents a new chapter in surgical pathology.
  • The study group included 50 women with a histological diagnosis of advanced cervical carcinoma (43 squamous, 3 adenosquamous, 2 adenocarcinoma, 1 glassy cell, and 1 undifferentiated; International Federation of Gynecology and Obstetrics stage Ib-III) receiving a platinum-based chemotherapy concomitant with external beam radiotherapy before radical surgery.
  • In most cases, morphological criteria are sufficient to make a diagnosis, but sometimes, the use of immunohistochemistry (keratins and CD68) is a mandatory method to reveal the nature of the lesion.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Hysterectomy. Neoadjuvant Therapy / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Cervix Uteri / drug effects. Cervix Uteri / radiation effects. Cervix Uteri / surgery. Combined Modality Therapy. Female. Humans. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317212.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 68238-35-7 / Keratins
  •  go-up   go-down


93. Kawakami F, Mikami Y, Kojima A, Ito M, Nishimura R, Manabe T: Diagnostic reproducibility in gastric-type mucinous adenocarcinoma of the uterine cervix: validation of novel diagnostic criteria. Histopathology; 2010 Mar;56(4):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic reproducibility in gastric-type mucinous adenocarcinoma of the uterine cervix: validation of novel diagnostic criteria.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunophenotyping. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology


94. Chura JC, Brooker D, Downs LS Jr: Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature. Gynecol Oncol; 2006 Oct;103(1):336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
  • We report a case of an adenocarcinoma arising in a defunctionalized bladder that presented as locally advanced endometrial carcinoma.
  • Examination revealed a mass protruding through the cervix and possibly involving the bladder anteriorly.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Urinary Diversion / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793125.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Macdonald OK, Chen J, Dodson M, Lee CM, Gaffney DK: Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol; 2009 Aug;32(4):411-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix.
  • OBJECTIVE: Lymph node (LN) metastasis portends a poor outcome in women with carcinoma of the uterine cervix.
  • We queried a large database to analyze the importance of number of positive LN and histology in relation to survival after radical hysterectomy and lymphadenectomy.
  • Pathologic LN involvement was associated with higher grade, higher stage, larger tumor size, and squamous cell histology.
  • Predictors for both cause specific and overall survival on multivariate analysis included number of involved LN, histology, tumor grade, tumor size, disease stage, and pelvis or paraaortic lymphatic involvement.
  • CONCLUSIONS: Adenocarcinoma histology independently predicted for a more aggressive phenotype, particularly in women with LN involvement.
  • LN positive disease in carcinoma of the cervix predicts a prognosis that is inversely related to the number of involved nodes.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Hysterectomy / methods. Lymph Nodes / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


96. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


97. McCluggage WG: Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology; 2007 Feb;39(1):97-111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry as a diagnostic aid in cervical pathology.
  • As with biopsies from other sites in the female genital tract, immunohistochemistry is now being increasingly used in cervical pathology as an aid to diagnosis.
  • In this review, I discuss applications of immunohistochemistry in diagnostic cervical pathology with a particular focus on recent developments.
  • Although much of this review focuses on glandular lesions, the value of markers, such as MIB1 and p16, in the assessment of pre-invasive cervical squamous lesions is discussed.
  • In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; markers of value in the diagnosis of minimal deviation adenocarcinoma, such as HIK1083; markers of value in distinguishing metastatic cervical adenocarcinoma in the ovary from primary ovarian endometrioid or mucinous adenocarcinoma.
  • Rarely ectopic prostatic tissue occurs in the cervix, which can be confirmed by positive staining with prostatic markers.
  • A panel of markers, comprising oestrogen receptor, vimentin, monoclonal carcinoembryonic antigen and p16, is of value in distinguishing between a cervical adenocarcinoma and an endometrial adenocarcinoma of endometrioid type.
  • Markers of use in the diagnosis of cervical neuroendocrine neoplasms, including small cell and large cell neuroendocrine carcinoma, are discussed.
  • It is stressed that small cell neuroendocrine carcinomas may be negative with most of the commonly used neuroendocrine markers and this does not preclude the diagnosis. p63, a useful marker of squamous neoplasms within the cervix, is of value in distinguishing small cell neuroendocrine carcinoma (p63 negative) from small cell squamous carcinoma (p63 positive) and in confirming that a poorly differentiated carcinoma is squamous in type.
  • [MeSH-major] Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365826.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 104
  •  go-up   go-down


98. Vieira SC, Sousa RB, Tavares MB, de Abreu BA, Ibiapina JO, de Sousa Oliveira AK, Zeferino LC: Changes in pulse oximetry after patent blue dye injection into the uterine cervix. Ann Surg Oncol; 2008 Oct;15(10):2862-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in pulse oximetry after patent blue dye injection into the uterine cervix.
  • BACKGROUND: To evaluate changes in pulse oximetry readings in patients with cervical carcinoma after the injection of patent blue dye into the uterine cervix for sentinel lymph node detection.
  • METHODS: Fifty-six patients underwent radical hysterectomy and bilateral pelvic lymphadenectomy for the treatment of International Federation of Gynecology and Obstetrics stage I or II cervical cancer.
  • Four milliliters of patent blue dye were injected into the cervix.
  • On the eve of surgery, all patients also received an injection of Dextran 500 labeled with technetium 99 m (Tc-99 m Dextran, 600 to 800 muCi) into the cervix and subsequently underwent pelvic lymphoscintigraphy.
  • Pulse oximetry readings began to decrease between 2 and 10 minutes after patent blue dye injection into the cervix and lasted for approximately 5 minutes.
  • CONCLUSION: The decrease in pulse oximetry readings after patent blue dye injection into the cervix was associated with larger tumors and tumors that surrounded the external cervical os.
  • [MeSH-major] Coloring Agents. Oximetry. Oxygen / blood. Rosaniline Dyes. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged. Prognosis. Sentinel Lymph Node Biopsy. Technetium


99. Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2010 Jul;34(7):915-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
  • Endometrial and endocervical adenocarcinomas may seem histologically identical and it can be difficult to determine primary site of origin based on morphology alone.
  • The TMA consisted of 214 endometrial carcinomas, 33 endocervical adenocarcinomas, and 36 problematic cases.
  • The endometrial and endocervical carcinomas represented usual endometrioid and mucinous types, and special variants (uterine serous carcinoma, uterine clear cell carcinoma, minimal deviation endocervical adenocarcinoma, cervical small cell carcinoma, adenoid basal cell carcinoma, mesonephric carcinoma).
  • Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Papillomaviridae / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomavirus Infections / diagnosis. Reproducibility of Results. Tissue Array Analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534993.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS775595; NLM/ PMC4847142
  •  go-up   go-down


100. Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T: Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett; 2008 Jun 8;264(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma.
  • This study investigated associations of Cap43 expression with angiogenesis and other clinicopathological factors in cervical adenocarcinoma.
  • The clinical records of 100 women who underwent surgery for cervical adenocarcinoma were reviewed retrospectively.
  • Our results suggest that increased expression of Cap43 is associated with angiogenesis and may be a poor prognostic indicator in women with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Neovascularization, Pathologic. Uterine Cervical Neoplasms / blood supply. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281151.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down






Advertisement